Heterocyclic compounds as kinase inhibitors, compositions and methods of use thereof

By developing novel heterocyclic compounds as RET kinase inhibitors, the problems of short-lived efficacy and severe side effects of existing RET inhibitors have been solved, achieving highly effective treatment for RET-related cancers.

CN119053596AInactive Publication Date: 2024-11-29JS INNOMED HLDG LTD +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202280095060.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2022-05-13
Publication Date
2024-11-29
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing RET kinase inhibitors have problems with short-lived efficacy and serious side effects when treating RET-related cancers. Furthermore, due to the inhibition of non-RET kinases, they cause dose-limiting toxicity, failing to fully realize the value of RET as a clinical therapeutic target.

Method used

To develop novel heterocyclic compounds as selective and potent RET kinase inhibitors that inhibit RET activity by contacting the RET protein, thereby treating RET-related diseases.

Benefits of technology

It provides better pharmacokinetic properties and higher RET selectivity, significantly improving the therapeutic effect on RET-related cancers and reducing side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119053596A_ABST
    Figure CN119053596A_ABST
Patent Text Reader

Abstract

# imgabs0 # disclosed herein are compounds of Formula I, and / or stereoisomers, stable isotopes, or pharmaceutically acceptable salts or solvates of compounds of Formula I; the present invention relates to compounds that are inhibitors of rearrangement during transfection (RET) and potentially useful in the treatment of RET-related diseases, such as RET-related cancers, as well as the therapeutic use of these compounds.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] Disclosed herein are novel heterocyclic compounds that can act as inhibitors of rearrangement during transfection (RET) kinase. Also disclosed herein are pharmaceutical compositions comprising at least one of such compounds, and methods of using at least one of such compounds in the treatment of RET-regulated diseases and disorders, such as cancer. Technical Background

[0002] RET is a transmembrane glycoprotein receptor tyrosine kinase (RTK) encoded by the RET oncogene (Borrello, MG, et al., Expert Opin. Ther. Targets. 2013, vol. 17, pp. 403-419). After homodimerization mediated by the GFL-GFRα complex, RET is activated via reverse autophosphorylation on tyrosine residues in the intracellular kinase domain. The phosphotyrosine residues of RET serve as docking sites for the SH2 domains of several signal transduction connectors, which activate several signal transduction cascades involved in cell proliferation (including RAS / MARK / ERK pathways, PI3K / Akt / mTOR pathways, and JAK / STAT pathways). There are several major genetic aberrations that cause RET activity to be dysregulated in many tumors. Among others, RET gene fusions and RET point mutations are RET mutations in many tumors. RET gene fusions are found in a variety of cancers, including 1-2% of non-small cell lung cancer (NSCLC), 20-30% of papillary thyroid cancer (PTC), and less than 1% of other cancers, such as pancreatic cancer, salivary gland cancer, spitz tumors, colorectal cancer, ovarian cancer, and myeloproliferative carcinoma. To date, at least 12 different fusion variants have been identified, with KIF5B-RET being the most common in NSCLC and CCDC6 and NCOA4 being the most common in PTC. RET point mutations occur primarily in sporadic medullary thyroid carcinoma (MTC, 30-50%) and hereditary MTC (100%), with RET M918T, G810R, V804L, and V804M being the most common mutations. In addition, overexpression of wild-type RET (through its physiological neurotrophic function) may play a role in the pathogenesis of other tumor types, such as pancreatic cancer.

[0003] Therefore, RET is a potential therapeutic target for cancer and other diseases with abnormal RET activity, such as gastrointestinal disorders (such as irritable bowel syndrome). Many multi-target kinase inhibitors with RET activity (cabozantinib, vandetanib, lenvatinib and alectinib) have been studied in clinical trials of cancer patients (Drilon, A. et al. Nat. Rev. Clin. Oncol., 2018, vol. 15, pp. 151-167). Although efficacy has been shown in certain tumor types, the clinical activity of such multi-target agents has been limited due to short duration and severe side effects. Due to the dose-limiting toxicological possibility caused by the main and more potent inhibition of non-RET kinases (such as VEGFR2) of such inhibitors, such inhibitors have not yet been clearly demonstrated to be of value as a clinically relevant therapeutic target. Therefore, there is a need for more potent and RET-selective inhibitor drugs with better drug-like properties (such as improved DMPK properties).

[0004] Public content overview

[0005] Disclosed herein are novel potent and selective RET kinase inhibitors, methods for preparing the same, and uses thereof. The compounds disclosed herein may have a strong cancer inhibitory effect and may effectively inhibit RET-related cancers.

[0006] Disclosed herein are compounds of formula I:

[0007]

[0008] and / or a stereoisomer, a stable isotope or a pharmaceutically acceptable salt or solvate of a compound, wherein A 1 , A 2 , L 1 , L 2 , R 1 , R 2 , X, Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , Y 6 and n are defined as follows.

[0009] A 1is a cyclic group selected from phenyl and 5- to 6-membered heteroaryl, wherein the 5- to 6-membered heteroaryl contains 1-2 heteroatoms independently selected from N, O and S as ring members, and wherein the cyclic group is optionally substituted by 1-3 groups independently selected from halogen elements, CN, C1-C4 alkyl and C1-C4 haloalkyl;

[0010] A 2 is a group selected from the following:

[0011]

[0012] The bond marked with an asterisk * represents the L of the connecting formula I 2 Keys;

[0013] L 1 is a group selected from the following:

[0014] Where R 3 and R 4 Each is independently selected from H and C1-C6 alkyl, wherein C1-C6 alkyl is optionally substituted by 1-3 groups independently selected from CN, halogen, OH and C1-C6 alkoxy; or wherein R 3 and R 4 Taken together, they form a group selected from the group consisting of carbonyl (oxo), 3- to 6-membered cycloalkyl, and a 5- to 6-membered heterocyclic ring containing 1-2 heteroatoms independently selected from N, O and S as ring members;

[0015] L 2 is a group selected from the following: CO, SO 1-2 , C1-C6 alkylene and C1-C6 haloalkylene;

[0016] R 1 Selected from -CN, ethynyl, halogen, -CF3, -CH3, -CH2CH3, cyclopropyl, -CH2CN and -CH(CN)CH3;

[0017] Each R 2 are independently selected from halogen, -OR 5 、-N(R 5 )2, -CN, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -OC(O)R 5 、-CO2R 5 、-C(O)N(R 5 )2, -C(=NR 6 )N(R 5 )2. -C(O)R 5 、-S(O) 0-2 R 7、-S(O)(=NR 6 )R 7 、-S(O) 1-2 N(R 5 )2、-N(R 5 )C(O)R 7 、-N(R 5 )C(=NR 6 )R 7 、-N(R 5 )S(O) 1-2 R 7 、-N(R 5 )C(O)N(R 5 )2、-N(R 5 )C(=NR 6 )N(R 5 )2、-N(R 5 )S(O) 1-2 N(R 5 )2 and -N(R 5 )CO2R 7 ,in:

[0018] Each R 5 independently selected from H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 haloalkyl, aryl, saturated and unsaturated 4-7 membered heterocyclyl containing 1-2 heteroatoms selected from N, O and S as ring members, and heteroaryl containing 1-4 heteroatoms selected from N, O and S as ring members;

[0019] Each R 6 Independently selected from H, -CN, -OH, C1-C4 alkyl and C1-C4 alkoxy;

[0020] Each R 7 independently selected from C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 haloalkyl, saturated and unsaturated 4-7 membered heterocyclyl containing 1-2 heteroatoms selected from N, O and S as ring members, aryl and heteroaryl containing 1-4 heteroatoms selected from N, O and S as ring members;

[0021] X is selected from -OH, -NH2, -CN, -NH(CO)(C1-C4 alkyl), C1-C4 alkyl, C1-C4 haloalkyl and C1-C4 alkoxy;

[0022] Y 1 , Y 2 , Y 3 , Y 4 , Y 5 and Y 6 Independently selected from N and -CR 8 , where R8 is selected from the group consisting of H, F, Cl, CN, CH3 and CF3; and

[0023] n is an integer selected from 1 to 3. Also disclosed herein is a pharmaceutical composition comprising a compound of Formula I disclosed herein and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of a compound of Formula I, and a pharmaceutically acceptable carrier.

[0024] Also disclosed herein is a method of inhibiting the activity of RET, comprising contacting protein RET with an effective amount of a compound of Formula I disclosed herein and / or a stereoisomer, stable isotope, or pharmaceutically acceptable salt or solvate of the compound of Formula I.

[0025] Also disclosed herein are methods of treating a disease treatable by inhibiting RET in a patient, the method comprising administering to a patient identified as needing such treatment an effective amount of a compound of Formula I and / or a stereoisomer, stable isotope, or pharmaceutically acceptable salt or solvate of a compound of Formula I disclosed herein.

[0026] Also disclosed herein is a method for treating a disease treatable by inhibiting RET in a patient, the method comprising administering to a patient identified as needing such treatment an effective amount of a pharmaceutical composition comprising a compound of Formula I disclosed herein and / or a stereoisomer, stable isotope, or pharmaceutically acceptable salt or solvate of a compound of Formula I, and a pharmaceutically acceptable carrier.

[0027] Also disclosed herein are methods of treating cancer in a patient, comprising administering to a patient identified as needing such treatment an effective amount of a pharmaceutical composition comprising a compound of Formula I disclosed herein and / or a stereoisomer, stable isotope, or pharmaceutically acceptable salt or solvate of a compound of Formula I, and a pharmaceutically acceptable carrier. In some embodiments, the cancer is selected from lung cancer, thyroid cancer, pancreatic cancer, salivary gland cancer, Spitz tumor, colorectal cancer, ovarian cancer, and myeloproliferative cancer.

[0028] Also disclosed herein is the use of a compound of Formula I and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of a compound of Formula I in the preparation of a medicament for treating a disease (such as cancer) that responds to inhibition of RET. In some embodiments, the cancer is selected from lung cancer, thyroid cancer, pancreatic cancer, salivary gland cancer, Spitz tumor, colorectal cancer, ovarian cancer, and myeloproliferative cancer.

[0029] Also disclosed herein are compounds of Formula I and subclasses of Formula I disclosed herein, and pharmaceutically acceptable salts or solvates of these compounds, and all stereoisomers (including diastereoisomers and enantiomers, and isotopically enriched variants thereof (including deuterium substitution)). These compounds can be used to treat conditions that respond to RET inhibition (such as those disclosed herein), and can be used to prepare drugs for treating these disorders. The pharmaceutical compositions and methods disclosed herein can also be used or formulated with co-therapeutic agents; for example, compounds of Formula I and sub-formulas thereof can be used or formulated with at least one agent selected from inhibitors of non-RET kinases or other therapeutic agents.

[0030] Also disclosed herein are methods and key intermediate compounds useful for making the compounds of Formula I disclosed herein.

[0031] As used herein, the following words, phrases and symbols are generally intended to have the meanings set forth below, unless the context in which they are used indicates otherwise. The following abbreviations and terms have the indicated meanings throughout this document.

[0032] Detailed description

[0033] The following definitions apply unless otherwise specified or obvious from the context:

[0034] A dash ("-") that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, -CONR a R b Attached through carbon atoms.

[0035] Unless expressly stated otherwise, the use of the terms "a," "an," etc. refers to one or more.

[0036] The term "halogen" or "halogen" herein refers to fluorine (F), chlorine (Cl), bromine (Br) or iodine (I). Groups and moieties substituted with halogens, such as alkyl groups substituted with halogens (haloalkyl) may be monohalogenated, polyhalogenated or perhalogenated. In some embodiments, unless otherwise specified, chlorine and fluorine are examples of halogen substituents on alkyl groups or cycloalkyl groups; unless otherwise specified, fluorine, chlorine and bromine are used, for example, on aryl groups or heteroaryl groups.

[0037] As used herein, unless otherwise specified, the term "heteroatom" or "hetero atom" refers to a nitrogen (N) atom or an oxygen (O) atom or a sulfur (S) atom (eg, nitrogen or oxygen).

[0038] As used herein, the term "optional" or "optionally" means that the subsequently described event or situation may or may not occur, and that the description includes situations in which the event or situation occurs and situations in which the event or situation does not occur. For example, "alkyl optionally substituted with X" includes both "alkyl not substituted with X" and "alkyl substituted with X". It will be understood by those skilled in the art that for any group containing one or more substituents, such a group is not intended to introduce any substitution or substitution pattern that is sterically impractical, synthetically unfeasible, and / or inherently unstable in water for long enough to be administered as a pharmaceutical formulation at room temperature. When multiple substituents are present, unless otherwise stated, the substituents are independently selected, so that in the presence of 2 or 3 substituents, for example, those substituents may be the same or different.

[0039] In some embodiments, "replacing with at least one group" means that one hydrogen on the specified atom or group is replaced with one selected from the specified group of substituents. In some embodiments, "replacing with at least one group" means that two hydrogens on the specified atom or group are independently replaced with two selected from the specified group of substituents. In some embodiments, "replacing with at least one group" means that three hydrogens on the specified atom or group are independently replaced with three selected from the specified group of substituents. In some embodiments, "replacing with at least one group" means that four hydrogens on the specified atom or group are independently replaced with four selected from the specified group of substituents.

[0040] The term "alkyl" herein refers to a hydrocarbon group selected from straight and branched saturated hydrocarbon groups having up to 18 carbon atoms, such as from 1 to 12 carbon atoms, further such as from 1 to 8 carbon atoms, and even further such as from 1 to 6 carbon atoms. Representative examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, n-decyl, and the like.

[0041] Unless expressly stated, an alkyl group may be optionally substituted with one or more substituents (such as one, two or three substituents, or 1 to 4 substituents, up to the number of hydrogen atoms present in the unsubstituted alkyl group) replacing the hydrogen atoms of the unsubstituted alkyl group. If not otherwise specified, suitable substituents for the alkyl group may be selected from halogen elements, D, CN, oxo, hydroxy, substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted 3-7 membered heterocycloalkyl containing 1 or 2 heteroatoms selected from N, O and S as ring members, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl containing 1 to 4 heteroatoms selected from N, O and S as ring members, amino, -NH(C1-C4 alkyl), -N(C1-C4 alkyl)2, -S(=O) 0-2 (C1-C4 alkyl), -S(=NR)(=O)(C1-C4 alkyl), -C(=O)(C1-C4 alkyl), -C(=NOH)(C1-C4 alkyl), -CO2H, -CO2(C1-C4 alkyl), -S(=O) 1-2 NH2, -S(=O) 1-2 NH(C1-C4 alkyl), -S(=O) 1-2 N(C1-C4 alkyl)2, -CONH2, -C(=O)NH(C1-C4 alkyl), -C(=O)N(C1-C4 alkyl)2, -C(=NOH)NH(C1-C4 alkyl), -OC(=O)(C1-C4 alkyl), -NHC(=O)(C1-C4 alkyl), -NHC(=NOH)(C1-C4 alkyl), -NH(C=O)NH2, -NHC(=O)O(C1-C4 alkyl), -NHC(=O)NH(C1-C4 alkyl), NHC(=NOH)NH(C1-C4 alkyl), -NHS(=O) 1-2 (C1-C4 alkyl), -NHS(=O) 1-2 NH2, and -NHS(=O) 1-2NH(C1-C4 alkyl); wherein the substituents for substituted C1-C4 alkoxy, substituted C3-C6 cycloalkyl, substituted 3-7 membered heterocycloalkyl, substituted aryl and substituted heteroaryl are up to three groups independently selected from halogen elements, D, -CN, C1-C4 alkyl, C1-C4 haloalkyl, oxo, hydroxy, C1-C4 alkoxy, amino, -NH(C1-C4 alkyl), -N(C1-C4 alkyl)2. In some embodiments, unless otherwise specified, the substituents of the alkyl group are selected from, for example, halogen elements, CN, oxo, hydroxyl, C1-C4 alkoxy, C3-C6 cycloalkyl, phenyl, amino, -NH(C1-C4 alkyl), -N(C1-C4 alkyl)2, C1-C4 alkylthio, C1-C4 alkylsulfonyl, -C(=O)(C1-C4 alkyl), -CO2H, -CO2(C1-C4 alkyl), -OC(=O)(C1-C4 alkyl), -NHC(=O)(C1-C4 alkyl) and -NHC(=O)O(C1-C4 alkyl).

[0042] The term "alkoxy" herein refers to a straight or branched chain alkyl group comprising from 1 to 18 carbon atoms connected by an oxygen bridge (e.g., methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, pentoxy, 2-pentoxy, isopentoxy, neopentoxy, hexoxy, 2-hexoxy, 3-hexoxy, 3-methylpentoxy, etc.). Typically, the alkoxy group comprises from 1 to 6 carbon atoms (e.g., 1 to 4 carbon atoms) connected by an oxygen bridge.

[0043] Unless explicitly stated, an alkoxy group may be optionally substituted with one or more substituents (such as one, two or three substituents, or 1-4 substituents, up to the number of hydrogens present on the unsubstituted alkoxy group) replacing the hydrogen atoms of the unsubstituted alkyl portion of the alkoxy group. Unless otherwise specified, suitable substituents are selected from the substituents listed above for example for alkyl groups, except that hydroxyl and amino groups are generally not present on the carbon directly connected to the oxygen of the substituted alkyl-O group.

[0044] The term "alkenyl" herein refers to a hydrocarbon group selected from straight and branched hydrocarbon groups, the hydrocarbon group including at least one C=C double bond and from 2 to 18 (such as from 2 to 6) carbon atoms. Examples of alkenyl groups can be selected from ethenyl or vinyl (-CH═CH2), prop-1-enyl (-CH═CHCH3), prop-2-enyl (-CH2CH═CH2), 2-methylprop-1-enyl, but-1-enyl, but-2-enyl, but-3-enyl, but-1,3-dienyl, 2-methylbut-1,3-diene, hex-1-enyl, hex-2-enyl, hex-3-enyl, hex-4-enyl and hex-1,3-dienyl groups. The point of attachment can be on an unsaturated carbon or a saturated carbon.

[0045] Unless clearly stated, alkenyl groups may alternatively be replaced by one or more substituents (such as one, two or three substituents, or 1-4 substituents, up to the number of hydrogens present on the unsubstituted alkenyl groups) replacing the hydrogen atoms of unsubstituted alkenyl groups. Unless otherwise specified, otherwise suitable substituents are selected from the substituents listed above of, for example, alkyl groups.

[0046] The term "alkynyl" herein refers to a hydrocarbon group selected from straight and branched hydrocarbon groups, the hydrocarbon group including at least one -C≡C- triple bond and from 2 to 18 (such as from 2 to 6) carbon atoms. Examples of alkynyl groups include ethynyl (-C≡CH), 1-propynyl (-C≡CCH3), 2-propynyl (propargyl, -CH2C≡CH), 1-butynyl, 2-butynyl and 3-butynyl groups. The point of attachment can be on an unsaturated carbon or a saturated carbon.

[0047] Unless explicitly stated, alkynyl groups may be optionally substituted with one or more substituents (such as one, two or three substituents, or 1-4 substituents, up to the number of hydrogens present on the unsubstituted alkynyl group) replacing the hydrogen atoms of the unsubstituted alkynyl group. Unless otherwise specified, suitable substituents are selected from the substituents listed above for example for alkyl groups.

[0048] The term "alkylene" refers to a divalent alkyl group including from 1 to 10 carbon atoms and two expanded valence bonds for connection to other molecular moieties. The two molecular moieties connected to the alkylene can be on the same carbon atom or on different carbon atoms; thus, for example, propylene is a 3-carbon alkylene that can be 1,1-disubstituted, 1,2-disubstituted or 1,3-disubstituted. Unless otherwise specified, alkylene refers to a moiety including from 1 to 6 carbon atoms (such as from 1 to 4 carbon atoms). Representative examples of alkylene include, but are not limited to, methylene, ethylene, n-propylene, isopropylene, n-butylene, sec-butylene, isobutylene, tert-butylene, n-pentylene, isopentylene, neopentylene, n-hexylene, 3-methylhexylene, 2,2-dimethylpentylene, 2,3-dimethylpentylene, n-heptylene, n-octylene, n-nonylene, n-decylene, etc. Substituted alkylene is an alkylene group containing one or more (such as one, two or three) substituents; unless otherwise specified, suitable substituents are selected from, for example, the substituents listed above for alkyl groups.

[0049] Unless explicitly stated, alkylene groups may be optionally substituted with one or more substituents (such as one, two or three substituents, or 1-4 substituents, up to the number of hydrogens present in the unsubstituted alkylene group) replacing the hydrogen atoms of unsubstituted alkylene groups. Unless otherwise specified, suitable substituents are selected from the substituents listed above for example for alkyl groups.

[0050] Similarly, "alkenylene" and "alkynylene" refer to alkylene groups that include double or triple bonds, respectively; for example, they are 2-6 (eg, 2-4) carbon atoms in length, and can be substituted as discussed above for alkylene groups.

[0051] The term "haloalkyl" refers to an alkyl group defined herein that is substituted by one or more halogen groups defined herein. Unless otherwise specified, the alkyl portion of a haloalkyl group includes 1-4 carbon atoms. A haloalkyl group may be a monohaloalkyl group, a dihaloalkyl group, a trihaloalkyl group, or a polyhaloalkyl group (including a perhaloalkyl group). A monohaloalkyl group may have an iodine, bromine, chlorine, or fluorine group in the alkyl group. A dihaloalkyl group and a polyhaloalkyl group may have two or more or a combination of different halogen groups in the same halogen atom in the alkyl group. Polyhaloalkyl groups include, for example, up to 6, or 4, or 3, or 2 halogen groups. Examples of haloalkyl groups include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, and dichloropropyl. A perhaloalkyl group refers to an alkyl group (for example, trifluoromethyl) in which all hydrogen atoms are replaced by halogen atoms. In some embodiments, unless otherwise specified, haloalkyl groups include monofluoro-, difluoro-, and trifluoro-substituted methyl and ethyl groups (eg, -CF3, -CF2H, -CFH2, and -CH2CF3).

[0052] Unless explicitly stated, haloalkyl groups may be optionally substituted with one or more substituents (such as one, two or three substituents, or 1-4 substituents, up to the number of hydrogens present in the unsubstituted haloalkyl group) replacing the hydrogen atoms of unsubstituted haloalkyl. Unless otherwise specified, suitable substituents are selected from the substituents listed above for example for alkyl groups.

[0053] As used herein, the term "haloalkoxy" refers to haloalkyl-O-, wherein haloalkyl is as defined above. Examples of haloalkoxy include, but are not limited to, fluoromethoxy, difluoromethoxy, trifluoromethoxy, trichloromethoxy, 2-chloroethoxy, 2,2,2-trifluoroethoxy, 1,1,1,3,3,3-hexafluoro-2-propoxy, and the like. In some embodiments, the haloalkoxy group includes 1-4 carbon atoms and up to three halogen elements (e.g., monofluoro, difluoro, and trifluoro substituted methoxy and ethoxy groups.

[0054] Unless explicitly stated, haloalkoxy groups may be optionally substituted with one or more substituents (such as one, two or three substituents, or 1-4 substituents, up to the number of hydrogens present in the unsubstituted haloalkoxy groups) replacing the hydrogen atoms of the unsubstituted alkyl moiety of the alkoxy group. Unless otherwise specified, suitable substituents are selected from the substituents listed above for example for alkyl groups, except that hydroxyl and amino groups are usually not present on the carbon directly connected to the oxygen of the substituted haloalkyl-O group.

[0055] The term "cycloalkyl" herein refers to a hydrocarbon group selected from saturated and partially unsaturated cycloalkyl groups (such as monocyclic and polycyclic (e.g., bicyclic and tricyclic, adamantyl and spirocycloalkyl) groups) including from 3 to 20 carbon atoms. A monocyclic alkyl group is a cycloalkyl group including from 3 to 20 carbon atoms (such as from 3 to 8 carbon atoms). Examples of monocyclic cycloalkyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl, cyclododecyl and cyclohexenyl. Bicyclic alkyl groups include bridged bicyclic alkyls, fused bicyclic alkyls and spirocycloalkyls. A bridged bicyclic alkyl contains a monocyclic cycloalkyl ring in which two non-adjacent carbon atoms of the monocyclic ring are connected by an alkylene bridge (i.e., in the form of -(CH2)) of one to three additional carbon atoms. n -bridged groups, wherein n is 1, 2, or 3). Examples of bridged bicycloalkyls include, but are not limited to, bicyclo[2.2.1]heptene, bicyclo[3.1.1]heptane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, bicyclo[3.3.1]nonane, and bicyclo[4.2.1]nonane. Fused bicycloalkyls contain a monocyclic cycloalkyl ring fused to a phenyl, monocyclic cycloalkyl, or monocyclic heteroaryl. Examples of fused bicycloalkyls include, but are not limited to, bicyclo[4.2.0]octa-1,3,5-triene, 2,3-dihydro-1H-indene, 6,7-dihydro-5H-cyclopenta[b]pyridine, 5,6-dihydro-4H-cyclopenta[b]thiophene, and decalin, and the like. Spirocycloalkyl contains two monocyclic ring systems that share two carbon atoms forming a bicyclic ring system. Examples of spirocycloalkyl include, but are not limited to: Bicyclic cycloalkyl groups include, for example, from 7 to 12 carbon atoms. Monocyclic alkyl or bicyclic alkyl is connected to the parent molecular moiety through any carbon atom contained in the cycloalkyl ring. Tricyclic alkyl groups include bridged tricyclic alkyl as used herein, and bridged tricyclic alkyl refers to: 1) a bridged bicyclic alkyl ring, wherein two non-adjacent carbon atoms of the bridged bicyclic alkyl ring are connected by an alkylene bridge (i.e., in the form of -(CH2)) of one to three additional carbon atoms. n -, where n is 1, 2, or 3) to connect, or 2) to a fused bicyclic alkyl ring in which the two non-shared ring atoms on each ring are linked by an alkylene bridge of one to three additional carbon atoms (i.e., of the form -(CH2) n - bridging group, wherein n is 1, 2 or 3), wherein "fused bicycloalkyl ring" refers to a monocycloalkyl ring fused to a monocycloalkyl ring. Examples of bridged tricycloalkyl groups include, but are not limited to, adamantyl As used herein, bridged tricycloalkyl is attached to the parent molecular moiety through any ring atom. Ring atoms disclosed herein refer to carbon atoms on the ring skeleton. Cycloalkyl can be saturated or include at least one double bond (i.e., partially unsaturated), but not completely conjugated, and is not aromatic (as aromatic is defined herein). Cycloalkyl can be substituted by at least one heteroatom selected from, for example, O, S and N.

[0056] Unless explicitly stated, cycloalkyl groups may be optionally substituted with one or more substituents (such as one, two or three substituents, or 1-4 substituents, up to the number of hydrogens present in the unsubstituted cycloalkyl groups) replacing the hydrogen atoms of unsubstituted cycloalkyl. In some embodiments, substituted cycloalkyl includes 1-4 (such as 1-2) substituents. Unless otherwise specified, suitable substituents are selected from the substituents listed above for example of alkyl groups.

[0057] The term "cycloalkylene" or "cycloalkylene ring" disclosed herein refers to a divalent cycloalkane ring connected through the same carbon atom of the cycloalkane ring by removing two hydrogen atoms from the same carbon atom. Examples of cycloalkylene rings include, but are not limited to, cyclopropylene, cyclobutylene, cyclopentylene, and cyclohexylene. It can be represented in an illustrative manner by the following structure, wherein n is 1, 2, 3, 4, or 5.

[0058]

[0059] The terms "heterocycloalkyl", "heterocyclyl" or "heterocycle" disclosed herein refer to "cycloalkyl" as defined above having at least one ring carbon atom replaced by a heteroatom independently selected from O, N, S. The heterocyclyl includes, for example, 1, 2, 3 or 4 heteroatoms, and N, C or S can be independently oxidized in the cyclic ring system. The N atom can also be substituted to form a tertiary amine or an ammonium salt. The point of attachment of the heterocyclyl can be on a heteroatom or carbon. "Heterocyclyl" herein also refers to a 5- to 7-membered saturated or partially unsaturated carbocyclic ring (heterocycle) including at least one heteroatom selected from, for example, N, O and S, which is fused to a 5-, 6- and / or 7-membered cycloalkyl, heterocyclic or carbocyclic aromatic ring, provided that when the heterocyclic ring is fused to the carbocyclic aromatic ring, the point of attachment is at the heterocyclic ring, and when the heterocyclic ring is fused to the cycloalkyl, the point of attachment can be at the cycloalkyl or heterocyclic ring. "Heterocyclyl" herein also refers to an aliphatic spirocycle including at least one heteroatom selected from, for example, N, O and S. The ring may be saturated or have at least one double bond (i.e., partially unsaturated). The heterocyclic group may be substituted, for example, by an oxo group. The point of attachment may be carbon or a heteroatom. The heterocyclic group is not a heteroaryl group as defined herein.

[0060] Examples of heterocycles include, but are not limited to, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperidinyl, piperazinyl, pyranyl, morpholinyl, oxiranyl, aziridinyl, thiirane, azetidinyl, oxetanyl, thietanyl, dithietanyl, dihydropyridinyl, tetrahydropyridinyl, thiomorpholinyl, thioxanyl, homopiperazinyl, homopiperidinyl, azepanyl, oxetanyl, thietanyl, oxathianyl, dioxetanyl, oxathian ... Base, diazepine Base, thiazolyl 1-oxo-1-thiomorpholinyl, 1,1-dioxo-1-thiomorpholinyl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, and azabicyclo[2.2.2]hexanyl. Substituted heterocycles also include ring systems substituted with one or more oxo moieties, such as piperidinyl N-oxide, morpholinyl-N-oxide, 1-oxo-1-thiomorpholinyl, 1,1-dioxo-1-thiomorpholinyl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, and azabicyclo[2.2.2]hexanyl. Substituted heterocycles also include ring systems substituted with one or more oxo moieties, such as piperidinyl N-oxide, morpholinyl-N-oxide, 1-oxo-1-thiomorpholinyl, 1,1-dioxo-1-thiomorpholinyl,

[0061] Unless explicitly stated, the heterocyclic radical group may be optionally substituted with one or more substituents (such as one, two or three substituents, or 1-4 substituents, up to the number of hydrogens present in the unsubstituted heterocyclic radical group) replacing the hydrogen atoms of the unsubstituted heterocyclic radical. In some embodiments, the substituted heterocycloalkyl group includes 1-4 (such as 1-2) substituents. Unless otherwise specified, suitable substituents are selected from the substituents listed above of, for example, alkyl groups.

[0062] The term "aryl" refers to an aromatic hydrocarbon group including 5-15 carbon atoms in the ring portion. In some embodiments, aryl refers to a group selected from 5- and 6-membered carbocyclic aromatic rings, for example, phenyl; a bicyclic ring system (such as a 7- to 12-membered bicyclic ring system, wherein at least one ring is carbocyclic and aromatic) selected from, for example, naphthalene, indane, and 1,2,3,4-tetrahydroquinoline; and a tricyclic ring system (such as a 10- to 15-membered tricyclic ring system, wherein at least one ring is carbocyclic and aromatic), for example, fluorene.

[0063] In some embodiments, aryl groups are selected from 5 yuan and 6 yuan of carbocyclic aromatic rings fused to 5 yuan to 7 yuan cycloalkyl or optionally including at least one heterocycle (as defined in "heterocyclyl" or "heterocycle" below) selected from the heteroatoms of N, O and S, with the condition that when the carbocyclic aromatic ring is fused with the heterocycle, the connection point is at the carbocyclic aromatic ring, and when the carbocyclic aromatic ring is fused with the cycloalkyl group, the connection point can be at the carbocyclic aromatic ring or at the cycloalkyl group. The divalent groups formed by substituted benzene derivatives and having free valence at the ring atoms are named as substituted phenylene groups. The divalent groups obtained by removing a hydrogen atom from the monovalent polycyclic hydrocarbon radical ending with "-base" from the carbon atom with free valence are named by adding "-subunit" to the name of the corresponding monovalent group, for example, the naphthyl group with two connection points is called naphthylene. However, aryl does not include heteroaryl or does not overlap with heteroaryl in any way, and is defined separately below. Thus, if one or more carbocyclic aromatic rings are fused to a heterocyclic aromatic ring (eg, heteroaryl as defined below), the resulting ring system is heteroaryl (and not aryl) as defined herein.

[0064] Unless explicitly stated, aryl groups may be optionally substituted with one or more substituents (such as one, two or three substituents, or 1-4 substituents, up to the number of hydrogens present on the unsubstituted aryl groups) replacing the hydrogen atoms of unsubstituted aryl. In some embodiments, substituted aryl groups include 1-5 substituents. Unless otherwise specified, suitable substituents are selected from the substituents listed above of, for example, alkyl groups.

[0065] The term "heteroaryl" as used herein refers to a group selected from a 5- to 7-membered aromatic monocyclic ring including at least one (e.g., from 1 to 4 heteroatoms, or in some embodiments, from 1 to 3 heteroatoms) heteroatom selected from, for example, N, O, and S, wherein the remaining ring atoms are carbon; an 8- to 12-membered bicyclic ring including at least one (e.g., from 1 to 4 heteroatoms, or in some embodiments, from 1 to 3 heteroatoms, or in other embodiments, 1 or 2 heteroatoms) heteroatom selected from, for example, N, O, and S, wherein the remaining ring atoms are carbon. is carbon, and wherein at least one ring is aromatic, and at least one heteroatom is present in the aromatic ring, and wherein the point of attachment is on any ring and on a carbon or heteroatom; and an 11- to 14-membered tricyclic ring comprising at least one (e.g., from 1 to 4 heteroatoms, or in some embodiments, from 1 to 3 heteroatoms, or in other embodiments, 1 or 2 heteroatoms) heteroatom selected from, for example, N, O, and S, wherein the remaining ring atoms are carbon, and wherein at least one ring is aromatic, and at least one heteroatom is present in the aromatic ring, and wherein the point of attachment is on any ring.

[0066] In some embodiments, the heteroaryl group comprises a 5- to 7-membered heterocyclic aromatic ring fused to a 5- to 7-membered cycloalkyl ring. For such fused bicyclic heteroaryl ring systems in which only one of the rings includes at least one heteroatom, the point of attachment can be at the heteroaryl ring or at the cycloalkyl ring.

[0067] In some embodiments, the heteroaryl group comprises a 5- to 7-membered heterocyclic aromatic ring fused to a 5- to 7-membered aryl ring. For such fused bicyclic heteroaryl ring systems in which only one of the rings includes at least one heteroatom, the point of attachment may be at the heteroaryl ring or at the aryl ring. Non-limiting examples include quinolyl and quinazolinyl.

[0068] In some embodiments, the heteroaryl group comprises a 5- to 7-membered heterocyclic aromatic ring fused to an additional 5- to 7-membered heterocyclic aromatic ring. Non-limiting examples include 1H-pyrazolo[3,4-b]pyridinyl and 1H-pyrrolo[2,3-b]pyridinyl.

[0069] When the total number of S atoms and O atoms in the heteroaryl group exceeds 1, those heteroatoms are not adjacent to each other. In some embodiments, the total number of S atoms and O atoms in the heteroaryl group does not exceed 2. In some embodiments, the total number of S atoms and O atoms in the heteroaromatic ring does not exceed 1.

[0070] Examples of heteroaryl groups include, but are not limited to, pyridyl, oxazolyl, pyrazinyl, pyrimidinyl, imidazolyl, imidazopyridinyl, isoxazolyl, oxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, tetrazolyl, thienyl, triazinyl, benzothienyl, furanyl, benzofuranyl, benzimidazolyl, indolyl, isoindolyl, indolinyl, phthalazinyl, pyrazinyl, pyridazinyl, pyrimidinyl, pyrrolyl, triazolyl, quinolyl, isoquinolyl, pyrazolyl, pyrrolopyridinyl (e.g., 1H-pyrrolo[2,3-b]pyridin-3-yl), pyrazolopyridinyl (e.g., 1H-pyrazolo[3,4-b]pyridin-3-yl), benzoxazolyl (e.g., benzo[ d]oxazol-6-yl), pteridinyl, purinyl, 1-oxa-2,3-oxadiazolyl, 1-oxa-2,4-oxadiazolyl, 1-oxa-2,5-oxadiazolyl, 1-oxa-3,4-oxadiazolyl, 1-thia-2,3-oxadiazolyl, 1-thia-2,4-oxadiazolyl, 1-thia-2,5-oxadiazolyl, 1-thia-3,4-oxadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, furopyridinyl, benzothiazolyl (e.g., benzo[d]thiazol-6-yl), indazolyl (e.g., 1H-indazol-5-yl), and 5,6,7,8-tetrahydroisoquinoline.

[0071] Unless explicitly stated, heteroaryl groups may be optionally substituted with one or more substituents (such as one, two or three substituents, or 1-4 substituents, up to the number of hydrogens present in the unsubstituted heteroaryl groups) replacing the hydrogen atoms of the unsubstituted heteroaryl groups. In some embodiments, the substituted heteroaryl groups include 1, 2 or 3 substituents. Unless otherwise specified, suitable substituents are selected from the substituents listed above for example for alkyl groups.

[0072] Compounds disclosed herein may contain asymmetric centers, and therefore may exist as enantiomers. In the case where compounds disclosed herein have two or more asymmetric centers, they may additionally exist as diastereomers. Enantiomers and diastereomers belong to the broader category of stereoisomers. It is well known in the art how to prepare optically active forms such as by resolving materials or by asymmetric synthesis. All such possible stereoisomers (such as substantially pure resolved enantiomers, their racemic mixtures, and mixtures of diastereomers) are intended to be included. All stereoisomers of compounds disclosed herein and / or their pharmaceutically acceptable salts are intended to be included. Unless otherwise explicitly mentioned, reference to an isomer is applicable to any one of the possible isomers. When the isomeric composition is not specified, all possible isomers are included.

[0073] When compounds disclosed herein contain olefinic double bonds, unless specified otherwise, such double bonds are intended to include both E and Z geometric isomers.

[0074] "Pharmaceutically acceptable salts" include, but are not limited to, salts formed with inorganic acids selected from, for example, hydrochlorides, phosphates, hydrogen phosphates, hydrobromides, sulfates, sulfinates, and nitrates; and salts formed with organic acids selected from, for example, malate, maleate, fumarate, tartrate, succinate, citrate, lactate, methanesulfonate, p-toluenesulfonate, 2-hydroxyethanesulfonate, benzoate, salicylate, stearate, alkanoate (e.g., acetate), and salts formed with HOOC-(CH2)n-COOH, wherein n is selected from 0 to 4. Similarly, examples of pharmaceutically acceptable cations include, but are not limited to, sodium, potassium, calcium, aluminum, lithium, and ammonium.

[0075] In addition, if the compounds disclosed herein are obtained in the form of acid addition salts, free bases can be obtained by alkalizing a solution of the acid salt. On the contrary, if the product is a free base, an addition salt (such as a pharmaceutically acceptable addition salt) can be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid according to the conventional procedures for preparing acid addition salts from basic compounds. Those skilled in the art will recognize various synthetic methods that can be used to prepare non-toxic pharmaceutically acceptable addition salts without excessive experimentation.

[0076] "Treating," "treat," "treatment," or "alleviation" refers to administering at least one compound disclosed herein, and / or at least one stereoisomer thereof (if any), at least one stable isotope thereof, or at least one pharmaceutically acceptable salt thereof, to a subject suffering from, for example, cancer, identified in need thereof.

[0077] The term "effective amount" refers to an amount of at least one compound disclosed herein, and / or at least one stereoisomer thereof (if any), at least one stable isotope thereof, or at least one pharmaceutically acceptable salt thereof, effective for "treating" a disease or disorder as defined above in a subject.

[0078] The terms "RET-related disease", "RET-related disorder", "RET-related cancer", "diseases and disorders regulated by RET" or "abnormal RET activity" refer to a disease, disorder or cancer associated with or having abnormal regulation of the RET gene. The abnormal regulation of the RET gene is caused by a RET gene mutation, which is composed of, for example, a RET gene translocation that causes the expression of a fusion protein; a deletion in the RET gene that causes the expression of a RET protein comprising at least one amino acid deletion compared to the wild-type RET protein; a mutation in the RET gene that causes the expression of a RET protein with one or more mutations; an alternative splicing version of the RET mRNA that causes a RET protein with at least one amino acid deletion in the RET protein; or a RET gene amplification that causes overexpression of the RET gene in a cell, thereby causing a pathogenic increase in the activity of the kinase domain of the RET protein or the constitutively active kinase domain of the RET protein in the cell. For example, at least 12 different fusion variants have been identified, of which KIF5B-RET is the most common in NSCLC, while CCDC6 and NCOA4 are the most common in PTC. Examples of RET point mutations include, but are not limited to, M918T, G810R, V804L, and V804M (Drilon, A. et al. Nat. Rev. Clin. Oncol., 2018, 15, 151-167). Examples of RET-related diseases or disorders include, but are not limited to, cancer and gastrointestinal disorders (such as irritable bowel syndrome).

[0079] Various embodiments are disclosed herein. It will be appreciated that the features specified in each embodiment can be combined with other specified features to provide additional embodiments of the present disclosure. The following listed embodiments are representative of the present disclosure.

[0080] Embodiment 1. Compound of formula I:

[0081]

[0082] and / or a stereoisomer, a stable isotope or a pharmaceutically acceptable salt or solvate of a compound, wherein:

[0083] A 1 is a cyclic group selected from phenyl and 5- to 6-membered heteroaryl, wherein the 5- to 6-membered heteroaryl contains 1-2 heteroatoms independently selected from N, O and S as ring members, and wherein the cyclic group is optionally substituted by 1-3 groups independently selected from halogen elements, CN, C1-C4 alkyl and C1-C4 haloalkyl;

[0084] A 2 is a group selected from the following:

[0085]

[0086] The bond marked with an asterisk * represents the L of the connecting formula I 2 Keys;

[0087] L 1 is a group selected from the following:

[0088] Where R 3 and R 4 Each is independently selected from H and C1-C6 alkyl, wherein C1-C6 alkyl is optionally substituted by 1-3 groups independently selected from CN, halogen, OH and C1-C6 alkoxy; or wherein R 3 and R 4 Taken together, they form a group selected from the group consisting of a carbonyl group, a 3- to 6-membered cycloalkyl group, and a 5- to 6-membered heterocyclic ring containing 1-2 heteroatoms independently selected from N, O and S as ring members;

[0089] L 2 is a group selected from the following: CO, SO 1-2 , C1-C6 alkylene and C1-C6 haloalkylene;

[0090] R 1 Selected from -CN, ethynyl, halogen, -CF3, -CH3, -CH2CH3, cyclopropyl, -CH2CN and -CH(CN)CH3;

[0091] Each R 2 are independently selected from halogen, -OR 5 、-N(R 5 )2, -CN, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -OC(O)R 5 、-CO2R 5 、-C(O)N(R 5 )2, -C(=NR 6 )N(R 5 )2. -C(O)R 5 、-S(O) 0-2 R 7 、-S(O)(=NR 6 )R 7 、-S(O) 1-2 N(R 5 )2、-N(R 5 )C(O)R 7 、-N(R 5 )C(=NR 6 )R 7、-N(R 5 )S(O) 1-2 R 7 、-N(R 5 )C(O)N(R 5 )2、-N(R 5 )C(=NR 6 )N(R 5 )2、-N(R 5 )S(O) 1-2 N(R 5 )2 and -N(R 5 )CO2R 7 ,in:

[0092] Each R 5 independently selected from H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 haloalkyl, aryl, saturated and unsaturated 4-7 membered heterocyclyl containing 1-2 heteroatoms selected from N, O and S as ring members, and heteroaryl containing 1-4 heteroatoms selected from N, O and S as ring members;

[0093] R 6 Independently selected from H, -CN, -OH, C1-C4 alkyl and C1-C4 alkoxy;

[0094] R 7 independently selected from C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 haloalkyl, saturated and unsaturated 4-7 membered heterocyclyl containing 1-2 heteroatoms selected from N, O and S as ring members, aryl and heteroaryl containing 1-4 heteroatoms selected from N, O and S as ring members;

[0095] X is selected from -OH, -NH2, -CN, -NH(CO)(C1-C4 alkyl), C1-C4 alkyl, C1-C4 haloalkyl and C1-C4 alkoxy;

[0096] Y 1 , Y 2 , Y 3 , Y 4 , Y 5 and Y 6 Independently selected from N and -CR 8 , where R 8 is selected from the group consisting of H, F, Cl, CN, CH3 and CF3; and

[0097] n is an integer selected from 1-3.

[0098] Embodiment 2. The compound as described in Embodiment 1, and / or the stereoisomer, stable isotope or pharmaceutically acceptable salt or solvate of the compound, wherein A 1is a cyclic group selected from phenyl, pyridine, pyrimidine, pyrazine, pyridazine, pyrazole, thiophene, thiazole and oxazole, and wherein the cyclic group is optionally substituted by 1-3 groups independently selected from halogen elements, CN, C1-C4 alkyl and C1-C4 haloalkyl.

[0099] Embodiment 3. The compound as described in Embodiment 1 or Embodiment 2, and / or the stereoisomer, stable isotope or pharmaceutically acceptable salt or solvate of the compound, wherein A 1 is a cyclic group selected from the following:

[0100]

[0101] The bond marked with an asterisk * represents the L of the connecting formula I 1 key.

[0102] Embodiment 4. The compound as described in Embodiment 1, and / or the stereoisomer, stable isotope or pharmaceutically acceptable salt or solvate of the compound, wherein A 1 is a cyclic group selected from 5- to 6-membered heteroaryl groups, wherein the 5- to 6-membered heteroaryl groups contain 1-2 heteroatoms independently selected from N, O and S as ring members, and wherein the cyclic group is optionally substituted by 1-3 groups independently selected from halogen elements, CN, C1-C4 alkyl and C1-C4 haloalkyl.

[0103] Embodiment 5. The compound as described in Embodiment 1 or Embodiment 4, and / or the stereoisomer, stable isotope or pharmaceutically acceptable salt or solvate of the compound, wherein A 1 is a cyclic group selected from pyridine, pyrimidine, pyrazine, pyridazine, pyrazole, thiophene, thiazole and oxazole, and wherein the cyclic group is optionally substituted by 1-3 groups independently selected from halogen elements, CN, C1-C4 alkyl and C1-C4 haloalkyl.

[0104] Embodiment 6. A compound as described in any one of Embodiments 1-5, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of the compound, wherein A 1 is a cyclic group selected from the following:

[0105]

[0106] The bond marked with an asterisk * represents the L of the connecting formula I 1 key.

[0107] Embodiment 7. The compound as described in Embodiment 1, and / or the stereoisomer, stable isotope or pharmaceutically acceptable salt or solvate of the compound, wherein A 1is a cyclic group selected from 6-membered heteroaryl groups, wherein the 6-membered heteroaryl groups contain 1-2 heteroatoms independently selected from N, O and S as ring members, and wherein the cyclic group is optionally substituted by 1-3 groups independently selected from halogen elements, CN, C1-C4 alkyl and C1-C4 haloalkyl.

[0108] Embodiment 8. The compound as described in Embodiment 1 or Embodiment 7, and / or the stereoisomer, stable isotope or pharmaceutically acceptable salt or solvate of the compound, wherein A 1 is a cyclic group selected from pyridine, pyrimidine, pyrazine and pyridazine, and wherein the cyclic group is optionally substituted by 1-3 groups independently selected from halogen elements, CN, C1-C4 alkyl and C1-C4 haloalkyl.

[0109] Embodiment 9. A compound as described in any one of Embodiments 1-8, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of the compound, wherein A 1 is a cyclic group selected from the following:

[0110]

[0111] The bond marked with an asterisk * represents the L of the connecting formula I 1 key.

[0112] Embodiment 10. A compound as described in any one of Embodiments 1-9, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of the compound, wherein A 2 is a group selected from the following:

[0113]

[0114] The bond marked with an asterisk * represents the L of the connecting formula I 2 key.

[0115] Embodiment 11. A compound as described in any one of Embodiments 1-10, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of the compound, wherein A 2 yes The bond marked with an asterisk * represents the L of the connecting formula I 2 key.

[0116] Embodiment 12. A compound as described in any one of Embodiments 1-11, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of the compound, wherein L 1 is a group selected from the following: R 3 and R 4are independently selected from H and CH3; or R 3 and R 4 Together they form a group selected from a carbonyl group and a 3- to 4-membered cycloalkyl group.

[0117] Embodiment 13. A compound as described in any one of Embodiments 1-12, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of the compound, wherein L 1 is a group selected from the following: The bond marked with an asterisk * represents the bond connecting X of formula I.

[0118] Embodiment 14. A compound as described in any one of Embodiments 1-13, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of the compound, wherein L 1 yes The bond marked with an asterisk * represents the bond connecting X of formula I.

[0119] Embodiment 15. A compound as described in any one of Embodiments 1-14, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of the compound, wherein L 2 It is a group selected from CO and C1-C6 alkylene.

[0120] Embodiment 16. A compound as described in any one of Embodiments 1-15, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of the compound, wherein L 2 is a group selected from CO and -CH2-.

[0121] Embodiment 17. A compound as described in any one of Embodiments 1-16, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of the compound, wherein L 2 It is -CH2-.

[0122] Embodiment 18. A compound as described in any one of Embodiments 1-17, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of the compound, wherein R 1 Yes-CN.

[0123] Embodiment 19. A compound as described in any one of Embodiments 1-18, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of the compound, wherein each R 2 Independently selected from halogen elements, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl and C1-C6 alkoxy.

[0124] Embodiment 20. A compound as described in any one of Embodiments 1-19, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of the compound, wherein each R 2 Independently selected from halogen elements and C1-C6 alkoxy groups.

[0125] Embodiment 21. A compound as described in any one of Embodiments 1-20, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of the compound, wherein each R 2 It is -OCH3.

[0126] Embodiment 22. A compound as described in any of Embodiments 1-21, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of the compound, wherein X is selected from -OH, -NH2, -NH(CO)CH3, and -CH2CH3.

[0127] Embodiment 23. A compound as described in any one of Embodiments 1-22, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of the compound, wherein X is selected from -OH and -NH2.

[0128] Embodiment 24. A compound as described in any one of Embodiments 1-23, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of the compound, wherein X is -OH.

[0129] Embodiment 25. A compound as described in any one of Embodiments 1-24, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of the compound, wherein Y 2 is N, and Y 1 , Y 3 and Y 4 Independently selected from -CR 8 , where R 8 Selected from H, F, Cl, CN, CH3 and CF3.

[0130] Embodiment 26. A compound as described in any one of Embodiments 1-24, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of the compound, wherein Y 2 and Y 4 is N, and Y 1 and Y 3 Independently selected from -CR 8 , where R 8 Selected from H, F, Cl, CN, CH3 and CF3.

[0131] Embodiment 27. A compound as described in any one of Embodiments 1-24, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of the compound, wherein Y 1 and Y 3 is N, and Y 2 and Y 4 Independently selected from -CR 8 , where R 8 Selected from H, F, Cl, CN, CH3 and CF3.

[0132] Embodiment 28. A compound as described in any one of Embodiments 1-27, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of the compound, wherein Y 5 is N and Y 6 Selected from -CR 8 , where R 8 Selected from H, F, Cl, CN, CH3 and CF3.

[0133] Embodiment 29. A compound as described in any one of Embodiments 1-27, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of the compound, wherein Y 6 is N and Y 5 Selected from -CR 8 , where R 8 Selected from H, F, Cl, CN, CH3 and CF3.

[0134] Embodiment 30. A compound as described in any one of Embodiments 1-29, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of the compound, wherein R 8 It's H.

[0135] Embodiment 31. A compound as described in any one of Embodiments 1-30, and / or a stereoisomer, stable isotope or pharmaceutically acceptable salt or solvate of the compound, wherein n is 1.

[0136] Embodiment 32. The compound of Embodiment 1, wherein the compound is selected from the compound of IA:

[0137]

[0138] and / or a stereoisomer, a stable isotope or a pharmaceutically acceptable salt or solvate of a compound, wherein A 1 , A 2 , L 1 , L 2 , R 1 , R 2 , X, Y 5 , Y6 and n are the same as defined in Embodiment 1.

[0139] Embodiment 33. The compound of Embodiment 1, wherein the compound is selected from the compound of Formula IB:

[0140]

[0141] and / or a stereoisomer, a stable isotope or a pharmaceutically acceptable salt or solvate of a compound, wherein A 1 , A 2 , L 1 , L 2 , R 1 , R 2 , X, Y 5 , Y 6 and n are the same as defined in Embodiment 1.

[0142] Embodiment 34. The compound according to embodiment 1, wherein the compound is selected from the compounds of formula IC:

[0143]

[0144] and / or a stereoisomer, a stable isotope or a pharmaceutically acceptable salt or solvate of a compound, wherein A 1 , A 2 , L 1 , L 2 , R 1 , R 2 , X, Y 5 , Y 6 and n are the same as defined in Embodiment 1.

[0145] Embodiment 35. The compound as described in Embodiment 1, wherein the compound is selected from the compound of Formula ID:

[0146]

[0147] and / or a stereoisomer, a stable isotope or a pharmaceutically acceptable salt or solvate of a compound, wherein A 1 , A 2 , L 1 , L 2 , R 1 , R 2 , X, Y 1 , Y 2 , Y 3 , Y 4 and n are the same as defined in Embodiment 1.

[0148] Embodiment 36. The compound according to Embodiment 1, wherein the compound is selected from the compound of Formula IE:

[0149]

[0150] and / or a stereoisomer, a stable isotope or a pharmaceutically acceptable salt or solvate of a compound, wherein A 1 , A 2 , L 1 , L 2 , R 1 , R 2 , X, Y 1 , Y 2 , Y 3 , Y 4 and n are the same as defined in Embodiment 1.

[0151] Embodiment 37. The compound of embodiment 1, wherein the compound is selected from the compound of formula IIA:

[0152]

[0153] and / or a stereoisomer, a stable isotope or a pharmaceutically acceptable salt or solvate of a compound, wherein A 1 , L 1 , L 2 , R 1 , R 2 , X, Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , Y 6 and n are the same as defined in Embodiment 1.

[0154] Embodiment 38. The compound of Embodiment 1, wherein the compound is selected from the compound of Formula IIB:

[0155]

[0156] and / or a stereoisomer, a stable isotope or a pharmaceutically acceptable salt or solvate of a compound, wherein A 1 , L 1 , L 2 , R 1 , R 2 , X, Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , Y 6 and n are the same as defined in Embodiment 1.

[0157] Embodiment 39. The compound of embodiment 1, wherein the compound is selected from the compounds of formula IIC:

[0158]

[0159] and / or a stereoisomer, a stable isotope or a pharmaceutically acceptable salt or solvate of a compound, wherein A 1 , L 1 , L 2 , R 1 , R 2 , X, Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , Y 6 and n are the same as defined in Embodiment 1.

[0160] Embodiment 40. The compound according to Embodiment 1, wherein the compound is selected from the compounds of Formula IID:

[0161]

[0162] and / or a stereoisomer, a stable isotope or a pharmaceutically acceptable salt or solvate of a compound, wherein A 1 , L 1 , L 2 , R 1 , R 2 , X, Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , Y 6 and n are the same as defined in Embodiment 1.

[0163] Embodiment 41. The compound as described in Embodiment 1, wherein the compound is selected from the compound of Formula IIE:

[0164]

[0165] and / or a stereoisomer, a stable isotope or a pharmaceutically acceptable salt or solvate of a compound, wherein A 1 , L 1 , L 2 , R 1 , R 2 , X, Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , Y 6and n are the same as defined in Embodiment 1.

[0166] Embodiment 42. A compound selected from the following compounds, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of the compound:

[0167]

[0168]

[0169]

[0170]

[0171]

[0172] Embodiment 43. A pharmaceutical composition comprising a compound according to any one of Embodiments 1-42, and / or a stereoisomer, stable isotope, or pharmaceutically acceptable salt or solvate of the compound, in admixture with at least one pharmaceutically acceptable carrier.

[0173] Embodiment 44. A pharmaceutical composition as described in Embodiment 43, further comprising at least one therapeutic adjuvant or co-therapy, wherein at least one therapeutic adjuvant or co-therapy is selected from chemotherapeutic agents and other anti-cancer agents, apoptosis regulators, immunopotentiators, agents used in immunotherapy, immune checkpoint inhibitors, radiation, anti-tumor vaccines, agents used in cytokine therapy, signal transduction inhibitors, additional RET kinase inhibitors, and kinase inhibitors.

[0174] Embodiment 45. A pharmaceutical composition according to embodiment 44, wherein at least one therapeutic adjunct or co-therapy is combined with the compound in a single dosage form, or at least one therapeutic adjunct is administered simultaneously or sequentially as a separate dosage form.

[0175] Embodiment 46. A method of treating a RET-related disease in a patient in need thereof, the method comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound described in any one of Embodiments 1-42, and / or a stereoisomer, stable isotope, or pharmaceutically acceptable salt or solvate of the compound, or a pharmaceutical composition described in any one of Embodiments 43-45.

[0176] Embodiment 47. A method as described in Embodiment 46, wherein the method comprises determining whether the disease in the patient is a RET-related disease, and administering to the patient in need of such treatment a therapeutically effective amount of a compound described in any one of Embodiments 1-42, and / or a stereoisomer, stable isotope or pharmaceutically acceptable salt or solvate of the compound, or a pharmaceutical composition described in any one of Embodiments 43-45.

[0177] Embodiment 48. A method as described in embodiment 46 or embodiment 47, wherein the RET-related disease is a RET-related cancer, and the RET-related cancer has RET gene fusion, one or more point mutations in the RET gene, or RET gene amplification, and RET gene amplification causes overexpression of the RET gene, thereby leading to a pathogenic increase in the activity of the kinase domain of the RET protein or the constitutively active kinase domain of the RET protein.

[0178] Embodiment 49. A method as described in embodiment 46 or embodiment 47, wherein the RET-related disease is irritable bowel syndrome or other gastrointestinal disorders, irritable bowel syndrome or other gastrointestinal disorders have RET gene fusion, one or more point mutations in the RET gene, or RET gene amplification, which causes overexpression of the RET gene, thereby leading to a pathogenic increase in the activity of the kinase domain of the RET protein or the constitutively active kinase domain of the RET protein.

[0179] Embodiment 50. A method as described in embodiment 48, wherein the treatment includes administering at least one therapeutic adjuvant or combination therapy, and at least one therapeutic adjuvant or combination therapy is selected from chemotherapeutic agents and other anti-cancer agents, apoptosis regulators, immune enhancers, agents used in immunotherapy, immune checkpoint inhibitors, radiation, anti-tumor vaccines, agents used in cytokine therapy, signal transduction inhibitors, and kinase inhibitors.

[0180] Embodiment 51. A method as described in embodiment 50, wherein the step of administering the compound is performed simultaneously or consecutively with the step of administering the therapeutic auxiliary agent.

[0181] Embodiment 52. The method of embodiment 51, wherein the operation of administering a therapeutic adjuvant comprises an additional RET inhibitor, immunotherapy, or a combination thereof.

[0182] Embodiment 53. A method as described in embodiment 48, wherein the RET-related cancer is selected from lung cancer, papillary thyroid cancer, medullary thyroid cancer, differentiated thyroid cancer, recurrent thyroid cancer, refractory differentiated thyroid cancer, multiple endocrine neoplasia type 2A or 2B (MEN2A or MEN2B, respectively), pheochromocytoma, parathyroid hyperplasia, breast cancer, pancreatic cancer, salivary gland cancer, Spitz tumor, colorectal cancer, papillary renal cell carcinoma, gastrointestinal mucosal ganglioneuroma, cervical cancer, ovarian cancer and myeloproliferative cancer.

[0183] Embodiment 54. The method of any one of embodiments 46-53, wherein the compound of any one of embodiments 1-42, and / or a stereoisomer, stable isotope, or pharmaceutically acceptable salt or solvate of the compound, or the pharmaceutical composition of any one of embodiments 43-45 is administered orally.

[0184] Embodiment 55. Use of the compound described in any one of Embodiments 1-42, and / or the stereoisomer, stable isotope or pharmaceutically acceptable salt or solvate of the compound, or the pharmaceutical composition described in any one of Embodiments 42-45 as a drug in the manufacture of a drug for treating RET-related diseases or in a medicine for treating RET-related diseases.

[0185] Embodiment 56. The use as described in Embodiment 55, wherein the RET-related disease is RET-related cancer, and the RET-related cancer has RET gene fusion, one or more point mutations in the RET gene, or RET gene amplification, and RET gene amplification causes overexpression of the RET gene, thereby leading to pathogenic increase in the activity of the kinase domain of the RET protein or the constitutively active kinase domain of the RET protein.

[0186] Embodiment 57. The use as described in Embodiment 56, wherein the RET-related disease is irritable bowel syndrome or other gastrointestinal disorders, irritable bowel syndrome or other gastrointestinal disorders have RET gene fusion, one or more point mutations in the RET gene, or RET gene amplification, RET gene amplification causes overexpression of the RET gene, thereby leading to pathogenic increase in the activity of the kinase domain of the RET protein or the constitutively active kinase domain of the RET protein.

[0187] Embodiment 58. The use according to embodiment 56 or embodiment 57, wherein the RET-related cancer is selected from lung cancer, papillary thyroid cancer, medullary thyroid cancer, differentiated thyroid cancer, recurrent thyroid cancer, refractory differentiated thyroid cancer, multiple endocrine neoplasia type 2A or 2B (MEN2A or MEN2B, respectively), pheochromocytoma, parathyroid hyperplasia, breast cancer, pancreatic cancer, salivary gland cancer, Spitz tumor, colorectal cancer, papillary renal cell carcinoma, gastrointestinal mucosal ganglioneuroma, cervical cancer, ovarian cancer and myeloproliferative cancer.

[0188] Embodiment 59. The use according to any one of embodiments 55-58, wherein the medicament is formulated for oral administration.

[0189] Embodiment 60. A compound according to any one of embodiments 1-42, and / or a stereoisomer, a stable isotope or a pharmaceutically acceptable salt or solvate of the compound, or a pharmaceutical composition according to embodiments 43-45 for use in the treatment of a RET-related disease.

[0190] Embodiment 61. A compound or pharmaceutical composition for use as described in Embodiment 60, wherein the RET-related disease is a RET-related cancer, and the RET-related cancer has a RET gene fusion, one or more point mutations in the RET gene, or a RET gene amplification, and the RET gene amplification causes overexpression of the RET gene, thereby leading to a pathogenic increase in the activity of the kinase domain of the RET protein or the constitutively active kinase domain of the RET protein.

[0191] Embodiment 62. A compound or pharmaceutical composition for use according to embodiment 60, wherein the RET-related disease is irritable bowel syndrome or other gastrointestinal disorders, irritable bowel syndrome or other gastrointestinal disorders have RET gene fusion, one or more point mutations in the RET gene, or RET gene amplification, which causes overexpression of the RET gene, thereby resulting in a pathogenic increase in the activity of the kinase domain of the RET protein or the constitutively active kinase domain of the RET protein.

[0192] Embodiment 63. A compound or pharmaceutical composition for use as described in Embodiment 60 or Embodiment 61, wherein the RET-related disease is a RET-related cancer, and the use comprises determining whether the cancer in the patient is a RET-related cancer, and administering a therapeutically effective amount of the compound or pharmaceutical composition to a patient in need of such treatment.

[0193] Embodiment 64. A compound or pharmaceutical composition for use according to embodiment 61 or embodiment 63, wherein the RET-related cancer is selected from lung cancer, papillary thyroid cancer, medullary thyroid cancer, differentiated thyroid cancer, recurrent thyroid cancer, refractory differentiated thyroid cancer, multiple endocrine neoplasia type 2A or 2B (MEN2A or MEN2B, respectively), pheochromocytoma, parathyroid hyperplasia, breast cancer, pancreatic cancer, salivary gland cancer, Spitz tumor, colorectal cancer, papillary renal cell carcinoma, gastrointestinal mucosal ganglioneuroma, cervical cancer, ovarian cancer and myeloproliferative cancer.

[0194] Embodiment 65. A method for inhibiting the in vitro or in vivo RET kinase activity of RET-related cancer cells using a compound described in any one of Embodiments 1-42, and / or a stereoisomer, stable isotope or pharmaceutically acceptable salt or solvate of the compound, wherein the RET-related cancer cells have a RET gene fusion, one or more point mutations in the RET gene, or RET gene amplification, which causes overexpression of the RET gene, thereby resulting in a pathogenic increase in the activity of the kinase domain of the RET protein or the constitutively active kinase domain of the RET protein.

[0195] Embodiment 66. A method of treating a RET-related cancer in a patient who has developed resistance to a RET inhibitor, the method comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of any one of Embodiments 1-42, and / or a stereoisomer, stable isotope, or pharmaceutically acceptable salt or solvate of the compound, or a pharmaceutical composition of any one of Embodiments 43-45.

[0196] Embodiment 67. A method as described in Embodiment 66, wherein the method comprises: (a) determining RET mutations in cancer cells in a sample from a patient who has developed resistance to previous treatment with a RET inhibitor; and (b) administering a compound described in any one of Embodiments 1-42, and / or a stereoisomer, stable isotope, or pharmaceutically acceptable salt or solvate of the compound, or a pharmaceutical composition described in any one of Embodiments 43-45.

[0197] Embodiment 68. A method as described in Embodiment 66 or Embodiment 67, wherein the treatment comprises administering at least one therapeutic adjuvant or combination therapy, wherein at least one therapeutic adjuvant or combination therapy is selected from chemotherapeutic agents or other anti-cancer agents, apoptosis modulators, immune enhancers, agents used in immunotherapy, immune checkpoint inhibitors, radiation, anti-tumor vaccines, agents used in cytokine therapy, signal transduction inhibitors, and kinase inhibitors.

[0198] Embodiment 69. The method of embodiment 68, wherein administering a therapeutic adjunct comprises an additional RET inhibitor, immunotherapy, or a combination thereof.

[0199] Embodiment 70. A kit comprising a compound or a pharmaceutically acceptable salt of a compound according to any one of Embodiments 1-42, or a pharmaceutical composition according to any one of Embodiments 43-45, and a therapeutic aid.

[0200] In some embodiments, the compound of Formula I (e.g., a compound selected from the group consisting of compounds of Formula IA, Formula IB, Formula IC, Formula ID, Formula IE, Formula IIA, Formula IIB, Formula IIC, Formula IID, and Formula IE) has a chiral configuration that is in excess of its enantiomer, and thus the compound is optically active. For example, such compounds disclosed herein are substantially free of the opposite enantiomer (i.e., at least 95% of the compounds have the chirality shown above).

[0201] Also disclosed herein are pharmaceutical compositions comprising a compound of Formula I (e.g., a compound selected from the group consisting of Formula IA, Formula IB, Formula IC, Formula ID, Formula IE, Formula IIA, Formula IIB, Formula IIC, Formula IID, and Formula IE), and / or a stereoisomer, stable isotope, or pharmaceutically acceptable salt or solvate of a compound of Formula I, and a pharmaceutically acceptable carrier.

[0202] Also disclosed herein is a method for inhibiting the activity of RET, comprising contacting protein RET with an effective amount of a compound of Formula I disclosed herein (such as a compound selected from the group consisting of Formula IA, Formula IB, Formula IC, Formula ID, Formula IE, Formula IIA, Formula IIB, Formula IIC, Formula IID and Formula IE), and / or a stereoisomer, stable isotope, or pharmaceutically acceptable salt or solvate of a compound of Formula I.

[0203] Also disclosed herein is a method for treating a disease treatable by inhibiting RET in a patient, the method comprising administering to a patient identified as needing such treatment an effective amount of a compound of Formula I disclosed herein (e.g., a compound selected from the group consisting of Formula IA, Formula IB, Formula IC, Formula ID, Formula IE, Formula IIA, Formula IIB, Formula IIC, Formula IID, and Formula IE), and / or a stereoisomer, stable isotope, or pharmaceutically acceptable salt or solvate of a compound of Formula I.

[0204] Also disclosed herein is a method for treating a disease treatable by inhibiting RET in a patient, the method comprising administering to a patient identified as needing such treatment an effective amount of a pharmaceutical composition comprising a compound of Formula I disclosed herein (e.g., a compound selected from the group consisting of Formula IA, Formula IB, Formula IC, Formula ID, Formula IE, Formula IIA, Formula IIB, Formula IIC, Formula IID, and Formula IE), and / or a stereoisomer, stable isotope, or pharmaceutically acceptable salt or solvate of a compound of Formula I, and a pharmaceutically acceptable carrier.

[0205] Also disclosed herein are methods for treating cancer in a patient, comprising administering to a patient identified as needing such treatment an effective amount of a pharmaceutical composition comprising a compound of Formula I disclosed herein (e.g., a compound selected from the group consisting of Formula IA, Formula IB, Formula IC, Formula ID, Formula IE, Formula IIA, Formula IIB, Formula IIC, Formula IID, and Formula IE), and / or a stereoisomer, stable isotope, or pharmaceutically acceptable salt or solvate of a compound of Formula I, and a pharmaceutically acceptable carrier. In some embodiments, the cancer is colon cancer, gastric cancer, leukemia, lymphoma, melanoma, or pancreatic cancer.

[0206] Also disclosed herein are methods for treating an inflammatory disease in a patient, the method comprising administering to a patient identified as needing such treatment an effective amount of a pharmaceutical composition comprising a compound of Formula I disclosed herein (e.g., a compound selected from the group consisting of Formula IA, Formula IB, Formula IC, Formula ID, Formula IE, Formula IIA, Formula IIB, Formula IIC, Formula IID, and Formula IE), and / or a stereoisomer, stable isotope, or pharmaceutically acceptable salt or solvate of a compound of Formula I, and a pharmaceutically acceptable carrier. In some embodiments, the inflammatory disease is rheumatoid arthritis, psoriasis, or eczema.

[0207] Also disclosed herein is the use of a compound of Formula I (e.g., a compound selected from the group consisting of Formula IA, Formula IB, Formula IC, Formula ID, Formula IE, Formula IIA, Formula IIB, Formula IIC, Formula IID, and Formula IE), and / or a stereoisomer, stable isotope, or pharmaceutically acceptable salt or solvate of a compound of Formula I in the preparation of a medicament for treating a disease responsive to inhibition of RET (e.g., cancer). In some embodiments, the cancer is lung cancer, thyroid cancer, pancreatic cancer, salivary gland cancer, Spitz tumor, colorectal cancer, ovarian cancer, or myeloproliferative cancer.

[0208] Although the most appropriate route in any given case will depend on the specific host to which the active ingredient is being administered, and the nature and severity of the condition, pharmaceutical compositions comprising a compound of Formula I (e.g., a compound selected from the group consisting of compounds of Formula IA, Formula IB, Formula IC, Formula ID, Formula IE, Formula IIA, Formula IIB, Formula IIC, Formula IID, and Formula IE), and / or a stereoisomer, stable isotope, or pharmaceutically acceptable salt or solvate of a compound of Formula I, and a pharmaceutically acceptable carrier, can be administered in various known ways, such as orally, topically, rectally, parenterally, by inhalation spray, or via an implantable kit. As used herein, the term "parenteral" includes subcutaneous, intradermal, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional, and intracranial injection or infusion techniques. The compositions disclosed herein can be conveniently presented in unit dosage form and prepared by any method known in the art.

[0209] The compound of Formula I (e.g., a compound selected from the group consisting of compounds of Formula IA, Formula IB, Formula IC, Formula ID, Formula IE, Formula IIA, Formula IIB, Formula IIC, Formula IID, and Formula IE), and / or a stereoisomer, stable isotope, or pharmaceutically acceptable salt or solvate of a compound of Formula I can be orally administered in a solid dosage form (e.g., capsules, tablets, lozenges, dragees, granules, and powders) or in a liquid dosage form (e.g., elixirs, syrups, emulsions, dispersions, and suspensions). The compound of Formula I (e.g., a compound selected from the group consisting of compounds of Formula IA, Formula IB, Formula IC, Formula ID, Formula IE, Formula IIA, Formula IIB, Formula IIC, Formula IID, and Formula IE), and / or a stereoisomer, stable isotope, or pharmaceutically acceptable salt or solvate of a compound of Formula I can also be administered parenterally in a sterile liquid dosage form (e.g., dispersion, suspension, or solution). Other dosage forms that can be used to administer a compound of Formula I (e.g., a compound selected from the group consisting of compounds of Formula IA, Formula IB, Formula IC, Formula ID, Formula IE, Formula IIA, Formula IIB, Formula IIC, Formula IID, and Formula IE), and / or a stereoisomer, stable isotope, or pharmaceutically acceptable salt or solvate of a compound of Formula I include ointments, creams, drops, skin patches or powders for topical administration, ophthalmic solutions or suspensions for ocular administration (i.e., eye drops), aerosol sprays or powder compositions for inhalation or intranasal administration, or creams, ointments, sprays or suppositories for rectal or vaginal administration.

[0210] Gelatin capsules containing a compound of Formula I (e.g., a compound selected from the group consisting of compounds of Formula IA, Formula IB, Formula IC, Formula ID, Formula IE, Formula IIA, Formula IIB, Formula IIC, Formula IID, and Formula IE), and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of a compound of Formula I and at least one powdered carrier (selected from, for example, lactose, starch, a cellulose derivative, magnesium stearate, stearic acid, etc.) can also be used. Similar diluents can be used to prepare compressed tablets. Both tablets and capsules can be made into sustained release products to provide continuous release of the drug over a period of time. Compressed tablets can be sugar-coated or film-coated to mask any unpleasant taste and protect the tablet from environmental influences, or enteric-coated to selectively decompose in the gastrointestinal tract.

[0211] Liquid dosage forms for oral administration may also include at least one agent selected from coloring agents and flavoring agents to increase patient acceptance.

[0212] Typically, water, suitable oil, saline, dextrose (dextrose) (glucose) aqueous solution and related sugar solutions and glycols (such as propylene glycol or polyethylene glycol) can be examples of suitable carriers for injection. Solutions for parenteral administration can include water-soluble salts of at least one compound disclosed herein, at least one suitable stabilizer and at least one buffer substance (if necessary). Antioxidants (such as sodium bisulfite, sodium sulfite or ascorbic acid) alone or in combination can be examples of suitable stabilizers. Citric acid and its salts and sodium ethylenediaminetetraacetate can also be used as examples of suitable stabilizers. In addition, the injection can also include at least one preservative selected from, for example, benzalkonium chloride, methyl parahydroxybenzoate and propyl parahydroxybenzoate and chlorobutanol.

[0213] Pharmaceutically acceptable carriers are selected from, for example, carriers that are compatible with the active ingredient of the pharmaceutical composition (and in some embodiments, capable of stabilizing the active ingredient) and are harmless to the subject to be treated. For example, solubilizers such as cyclodextrins (which can form specific more soluble complexes with at least one compound disclosed herein and / or at least one pharmaceutically acceptable salt) can be used as pharmaceutical excipients for delivering the active ingredient. Examples of other carriers include colloidal silica, magnesium stearate, cellulose, sodium lauryl sulfate, and pigments (such as D&C yellow #10). Suitable pharmaceutically acceptable carriers are disclosed in Remington's Pharmaceutical Sciences, A. Osol (a standard reference text in the art).

[0214] The efficacy of a compound of Formula I (e.g., a compound selected from the group consisting of compounds of Formula IA, Formula IB, Formula IC, Formula ID, Formula IE, Formula IIA, Formula IIB, Formula IIC, Formula IID, and Formula IE) and / or a stereoisomer, stable isotope, or pharmaceutically acceptable salt or solvate of a compound of Formula I in treating cancer can be examined by in vivo assays. For example, a compound of Formula I (e.g., a compound selected from the group consisting of compounds of Formula IA, Formula IB, Formula IC, Formula ID, Formula IE, Formula IIA, Formula IIB, Formula IIC, Formula IID, and Formula IE) and / or a stereoisomer, stable isotope, or pharmaceutically acceptable salt or solvate of a compound of Formula I can be administered to an animal (e.g., a mouse model) having cancer, and its therapeutic effect can be obtained. A positive result in one or more of such tests is sufficient to increase the scientific knowledge base, and therefore sufficient to demonstrate the practicality of the tested compound and / or salt. Based on the results, an appropriate dosage range and route of administration for an animal (e.g., a human) can also be determined.

[0215] For administration by inhalation, a compound of Formula I (e.g., a compound selected from the group consisting of compounds of Formula IA, Formula IB, Formula IC, Formula ID, Formula IE, Formula IIA, Formula IIB, Formula IIC, Formula IID, and Formula IE), and / or a stereoisomer, stable isotope, or pharmaceutically acceptable salt or solvate of a compound of Formula I can be conveniently delivered as an aerosol spray from a pressurized pack or a nebulizer. A compound of Formula I (e.g., a compound selected from the group consisting of compounds of Formula IA, Formula IB, Formula IC, Formula ID, Formula IE, Formula IIA, Formula IIB, Formula IIC, Formula IID, and Formula IE), and / or a stereoisomer, stable isotope, or pharmaceutically acceptable salt or solvate of a compound of Formula I can also be delivered in the form of a powder (which can be formulated), and the powder composition can be inhaled with the aid of an inhalation powder inhaler device. An exemplary delivery system for inhalation can be a metered dose inhalation (MDI) aerosol, which can be formulated as a suspension or solution of a compound of Formula I (e.g., a compound selected from the group consisting of Formula IA, Formula IB, Formula IC, Formula ID, Formula IE, Formula IIA, Formula IIB, Formula IIC, Formula IID, and Formula IE), and / or a stereoisomer, stable isotope, or pharmaceutically acceptable salt or solvate of a compound of Formula I in at least one suitable propellant (selected from, for example, fluorocarbons and hydrocarbons).

[0216] For ocular administration, an ophthalmic preparation can be formulated with an appropriate weight percentage of a compound of Formula I (e.g., a compound selected from the group consisting of compounds of Formula IA, Formula IB, Formula IC, Formula ID, Formula IE, Formula IIA, Formula IIB, Formula IIC, Formula IID, and Formula IE), and / or a solution or suspension of a stereoisomer, stable isotope, or pharmaceutically acceptable salt or solvate of a compound of Formula I in an appropriate ophthalmic vehicle such that the compound of Formula I (e.g., a compound selected from the group consisting of compounds of Formula IA, Formula IB, Formula IC, Formula ID, Formula IE, Formula IIA, Formula IIB, Formula IIC, Formula IID, and Formula IE), and / or a stereoisomer, stable isotope, or pharmaceutically acceptable salt or solvate of a compound of Formula I remains in contact with the visual field for a sufficient period of time to allow the compound to penetrate into the cornea and internal areas of the eye.

[0217] Useful pharmaceutical dosage forms for administering a compound of Formula I (e.g., a compound selected from the group consisting of Formula IA, Formula IB, Formula IC, Formula ID, Formula IE, Formula IIA, Formula IIB, Formula IIC, Formula IID, and Formula IE), and / or a stereoisomer, stable isotope, or pharmaceutically acceptable salt or solvate of a compound of Formula I include, but are not limited to, hard and soft gelatin capsules, tablets, parenteral vascular injections, and oral suspensions.

[0218] The dosage administered will depend on a variety of factors (such as the age, health and weight of the recipient, the extent of the disease, the type of concurrent treatment (if any), the frequency of treatment, and the nature of the desired effect). Generally, the daily dose of the active ingredient may vary, for example, from 0.1 mg / day to 2000 mg / day. For example, 10-500 mg once a day or more per day may be effective to obtain the desired result.

[0219] In some embodiments, a compound of Formula I (e.g., a compound selected from the group consisting of Formula IA, Formula IB, Formula IC, Formula ID, Formula IE, Formula IIA, Formula IIB, Formula IIC, Formula IID, and Formula IE), and / or a stereoisomer, stable isotope, or pharmaceutically acceptable salt or solvate of a compound of Formula I can be present in a capsule in an amount of 1 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 50 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 125 mg, 150 mg, 200 mg, 250 mg, 300 mg, 400 mg, and 500 mg.

[0220] In some embodiments, a large number of unit capsules can be prepared by filling each standard two-piece hard gelatin capsule with, for example, 100 mg of a compound of Formula I (e.g., a compound selected from the group consisting of Formula IA, Formula IB, Formula IC, Formula ID, Formula IE, Formula IIA, Formula IIB, Formula IIC, Formula IID, and Formula IE), and / or a stereoisomer, stable isotope, or pharmaceutically acceptable salt or solvate of a compound of Formula I in powder form, 150 mg of lactose, 50 mg of cellulose, and 6 mg of magnesium stearate.

[0221] In some embodiments, a mixture of a compound of Formula I (e.g., a compound selected from the group consisting of compounds of Formula IA, Formula IB, Formula IC, Formula ID, Formula IE, Formula IIA, Formula IIB, Formula IIC, Formula IID, and Formula IE), and / or a stereoisomer, stable isotope, or pharmaceutically acceptable salt or solvate of a compound of Formula I and a digestible oil (e.g., soybean oil, cottonseed oil, or olive oil) can be prepared and injected into gelatin with the aid of a positive displacement pump to form soft gelatin capsules containing 75 mg or 100 mg of active ingredient. The capsules are washed and dried.

[0222] In some embodiments, a compound of Formula I (e.g., a compound selected from the group consisting of Formula IA, Formula IB, Formula IC, Formula ID, Formula IE, Formula IIA, Formula IIB, Formula IIC, Formula IID, and Formula IE), and / or a stereoisomer, stable isotope, or pharmaceutically acceptable salt or solvate of a compound of Formula I can be present in a tablet in an amount of 1 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 50 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 125 mg, 150 mg, 200 mg, 250 mg, 300 mg, 400 mg, and 500 mg.

[0223] In some embodiments, a large number of tablets can be prepared by conventional procedures so that the dosage unit includes, for example, 100 mg of a compound of Formula I (e.g., a compound selected from the group consisting of compounds of Formula IA, Formula IB, Formula IC, Formula ID, Formula IE, Formula IIA, Formula IIB, Formula IIC, Formula IID, and Formula IE), and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of a compound of Formula I, 0.2 mg of colloidal silica, 5 mg of magnesium stearate, 275 mg of microcrystalline cellulose, 11 mg of starch, and 98.8 mg of lactose. Appropriate coatings may be applied, for example, to increase palatability or delay absorption.

[0224] In some embodiments, a parenteral composition suitable for administration by injection can be prepared by stirring 1.5% by weight of a compound of Formula I (e.g., a compound selected from the group consisting of compounds of Formula IA, Formula IB, Formula IC, Formula ID, Formula IE, Formula IIA, Formula IIB, Formula IIC, Formula IID, and Formula IE) in 10% by volume propylene glycol, and / or a stereoisomer, stable isotope, or pharmaceutically acceptable salt or solvate of a compound of Formula I. The solution is made up to the desired volume with water for injection and sterilized.

[0225] In some embodiments, an aqueous suspension can be prepared for oral administration. For example, an aqueous suspension comprising 100 mg of a finely separated compound of Formula I (e.g., a compound selected from the group consisting of compounds of Formula IA, Formula IB, Formula IC, Formula ID, Formula IE, Formula IIA, Formula IIB, Formula IIC, Formula IID, and Formula IE), and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of a compound of Formula I, 100 mg of sodium carboxymethylcellulose, 5 mg of sodium benzoate, 1.0 g of sorbitol solution (USP), and 0.025 ml of vanillin per 5 ml can be used.

[0226] When a compound of Formula I (e.g., a compound selected from the group consisting of compounds of Formula IA, Formula IB, Formula IC, Formula ID, Formula IE, Formula IIA, Formula IIB, Formula IIC, Formula IID, and Formula IE), and / or a stereoisomer, stable isotope, or pharmaceutically acceptable salt or solvate of a compound of Formula I is administered stepwise or co-administered with at least one other therapeutic agent, the same dosage form can generally be used. When the drugs are administered in physical combination, the dosage form and route of administration should be selected based on the compatibility of the combined drugs. Therefore, the term "co-administration" is understood to include administration of at least two agents simultaneously or sequentially, or alternatively as a fixed dose combination of at least two active ingredients.

[0227] A compound of Formula I (e.g., a compound selected from compounds of Formula IA, Formula IB, Formula IC, Formula ID, Formula IE, Formula IIA, Formula IIB, Formula IIC, Formula IID, and Formula IE), and / or a stereoisomer, stable isotope, or pharmaceutically acceptable salt or solvate of a compound of Formula I can be administered as the sole active ingredient or in combination with at least one second active ingredient, wherein the at least one second active ingredient is selected from, for example, other active ingredients known to be useful for treating a target disease in a patient (e.g., cancer, including, for example, colon cancer, gastric cancer, leukemia, lymphoma, melanoma, and pancreatic cancer).

[0228] As used herein, the term "optical isomer" or "stereoisomer" refers to any of the various stereoisomer configurations that may exist for a given compound of the present disclosure, and includes geometric isomers. It should be understood that substituents can be attached to the chiral center of a carbon atom. The term "chirality" refers to molecules with non-overlapping properties on their mirror image partners, while the term "achirality" refers to molecules that overlap on their mirror image partners. The present disclosure includes enantiomers, diastereomers, or racemates of compounds. "Enantiomers" are a pair of stereoisomers that are non-overlapping mirror images of each other. A 1:1 mixture of a pair of enantiomers is a "racemic" mixture. Where appropriate, the term is used to specify a racemic mixture. "Diastereomers" are stereoisomers that have at least two asymmetric atoms but are not mirror images of each other. Absolute stereochemistry is specified according to the Cahn-lngold-Prelog IR-SJ system. When the compound is enantiomerically pure, the stereochemistry of each chiral carbon can be designated by R or S. Resolved compounds whose absolute configuration is unknown can be designated as (+) or (-), depending on the direction (right- or left-handed) in which they rotate plane polarized light at the wavelength of the sodium D line. Certain compounds described herein contain one or more asymmetric centers or axes and can thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that can be defined as (R)- or (S)- in terms of absolute stereochemistry.

[0229] Depending on the choice of starting materials and synthetic procedures, the compounds may exist in the form of one of the possible isomers or as a mixture thereof (e.g., as a pure optical isomer, or as a mixture of isomers (depending on the number of asymmetric carbon atoms, such as a racemate and a diastereomeric mixture)). The present disclosure encompasses all such possible isomers (including racemic mixtures, diastereomeric mixtures and optically pure forms). Optically active (R)- and (S)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If the compound contains a double bond, unless otherwise specified, the substituents may be in the E or Z configuration. If the compound contains a disubstituted cycloalkyl, unless otherwise specified, the cycloalkyl substituent may have a cis or trans configuration.

[0230] In many cases, the compounds of the present disclosure are capable of forming acid salts and / or basic salts due to the presence of amino groups and / or carboxyl groups or groups similar thereto. As used herein, the term "salt" refers to an acid addition salt or a base addition salt of a compound of the present disclosure. "Salt" particularly includes "pharmaceutically acceptable salts". The term "pharmaceutically acceptable salt" refers to salts that retain the biological effectiveness and properties of the compounds of the present disclosure and are generally not biologically or otherwise undesirable.

[0231] Pharmaceutically acceptable acid addition salts can be formed with inorganic and organic acids, for example, acetate, adipate, aluminum, ascorbate, aspartate, benzoate, benzenesulfonate, bromide / hydrobromide, bicarbonate / carbonate, bisulfate / sulfate, camphorsulfonate, hexanoate, chloride / hydrochloride, chloroprocaine, chlortheophyllonate, citrate, edetate, calcium edetate, ethandisulfonate, ethylsulfonate, ethylenediamine, fumarate, galactarate (mucate), glucoheptonate, gluconate, glucuronate, glutamate, glycolate, hexylresorcinate, resorcinate), hippurate, hydroiodide / iodide, hydroxynapthoate (xinapoate), isethionate, lactate, lactobionate, lauryl sulfate, lithium, malate, maleate, malonate, mandelate, methanesulfonate, methylsulfate, naphthoate, naphthoate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, pantothenate, phosphate / hydrogenphosphate / dihydrogenphosphate, polygalacturonate, procaine, propionate, salicylate, sebacate, stearate, subacetate, succinate, sulfate, sulfosalicylate, tannate, tartrate, bitartrate, toluenesulfonate, triphenylacetate, and trifluoroacetate. Additional lists of suitable salts can be found in, for example, REMINGTON'S PHARMACEUTICAL SCIENCES, 20th ed., Mack Publishing Company, Easton, Pa., (1985) and HANDBOOK OF PHARMACEUTICAL SALTS: PROPERTIES, SELECTION, AND USE, by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002). Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, trifluoroacetic acid, sulfosalicylic acid, etc.

[0232] Pharmaceutically acceptable base addition salts can be formed with inorganic or organic bases and can have inorganic or organic counterions.

[0233] Inorganic counterions of such basic salts include, for example, ammonium salts and metals of Groups I to XII of the Periodic Table. In certain embodiments, the counterion is selected from sodium, potassium, ammonium, alkylammonium having one to four C1-C4 alkyl groups, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include ammonium, potassium, sodium, calcium, and magnesium salts.

[0234] Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like. Suitable organic amines include isopropylamine, benzathine, choline salts, diethanolamine, diethylamine, lysine, meglumine, piperazine, and tromethamine.

[0235] Pharmaceutically acceptable salt disclosed herein can be synthesized by basic part or acidic part by conventional chemical method.Usually, by making the free acid form of these compounds react with the suitable alkali (hydroxide, carbonate, bicarbonate etc. of Na, Ca, Mg or K) of stoichiometric amount, or making the free alkali form of these compounds react with the suitable acid of stoichiometric amount, such salt can be prepared.Such reaction is usually carried out in water or in an organic solvent or in a mixture of water and organic solvent.Usually, in feasible situation, the use of non-aqueous medium (such as ether, ethyl acetate, tetrahydrofuran, toluene, trichloromethane, methylene dichloride, methanol, ethanol, isopropanol or acetonitrile) is desirable.

[0236] Any formula given herein is intended to represent an unlabeled form of a compound (i.e., a compound in which all atoms are present at natural isotopic abundance and is not isotopically enriched) as well as an isotopically enriched or labeled form. An isotopically enriched or labeled compound has a structure depicted by a formula given herein, except that at least one atom of the compound is replaced by an atom of the same element but having an atomic mass or mass number different from the atomic mass or atomic mass distribution found in nature. Examples of isotopes that can be incorporated into the enriched or labeled compounds of the present disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, and chlorine, such as 2 H. 3 H. 11 C. 13 C. 14 C. 15 N. 18 F. 31 P. 32 P. 35 S. 36 Cl and 125 I. The present disclosure encompasses various isotopically labeled compounds as defined herein, for example, wherein radioactive isotopes are present at levels significantly higher than the natural abundance of such isotopes (e.g. 3 H and 14C) those compounds or non-radioactive isotopes (such as 2 H and 13 C). These isotope-labeled compounds are useful in metabolic studies (using 14 C) Reaction kinetics studies (using e.g. 2 H or 3 H), detection techniques or imaging techniques (such as positron emission tomography (PET) or single photon emission computed tomography (SPECT) including drug or substrate tissue distribution determination), or radiotherapy of patients. In particular, 18 F or labeled compounds may be particularly desirable for PET studies or SPECT studies. Isotopically labeled compounds of Formula I can generally be prepared by conventional techniques known to those skilled in the art or by methods analogous to those described in the accompanying Examples and Preparations using appropriate isotopically labeled reagents in place of the unlabeled reagents previously employed.

[0237] In addition, the use of heavier isotopes, especially deuterium (i.e. 2 H or D)) substitution can provide certain therapeutic advantages derived from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements or improvement in therapeutic index). It should be understood that deuterium herein is considered a substituent of a compound of Formula I if incorporated at a level substantially above the natural isotopic abundance. The present disclosure encompasses isotopically enriched variants of the compounds (e.g., deuterated variants as well as undeuterated variants). Deuterated variants may be deuterated at a single site or at multiple sites.

[0238] The degree of incorporation of such isotopes, particularly deuterium, in an isotopically enriched compound can be defined by an isotopic enrichment factor. As used herein, the term "isotopic enrichment factor" means the ratio between the isotopic abundance of a particular isotope in a sample and the natural abundance of that isotope in a non-enriched sample. If a substituent in a compound of the present disclosure is designated as deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).

[0239] Pharmaceutically acceptable solvates according to the present disclosure include those in which the solvent of crystallization may be isotopically substituted (eg, D2O, d6-acetone, d6-DMSO), as well as solvates with non-enriched solvents.

[0240] Compounds of the present disclosure (e.g., compounds of Formula I (e.g., compounds selected from compounds of Formula IA, IB, IC, ID, IE, IIA, IIB, IIC, IID, and IE)) containing groups capable of acting as donors and / or acceptors of hydrogen bonds are capable of forming co-crystals with suitable co-crystal formers. These co-crystals can be prepared from compounds of Formula I (e.g., compounds selected from compounds of Formula IA, IB, IC, ID, IE, IIA, IIB, IIC, IID, and IE) by known co-crystal formation procedures. Such procedures comprise grinding, heating, co-subliming, co-melting, or contacting in solution a compound of Formula I (e.g., a compound selected from compounds of Formula IA, IB, IC, ID, IE, IIA, IIB, IIC, IID, and IE) with a co-crystal former under crystallization conditions and isolating the co-crystals thereby formed. Suitable co-crystal formers include those described in WO2004078163. Accordingly, the present disclosure also provides co-crystals comprising a compound of Formula I (e.g., a compound selected from the group consisting of Formula IA, Formula IB, Formula IC, Formula ID, Formula IE, Formula IIA, Formula IIB, Formula IIC, Formula IID, and Formula IE).

[0241] As used herein, the term "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drug stabilizers, binders, excipients, disintegrants, lubricants, sweeteners, flavor enhancers, dyes, etc. and combinations thereof, as known to those skilled in the art (see, e.g., Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289-1329). Except in the case where any conventional carrier is incompatible with the active ingredient, its use in a therapeutic composition or pharmaceutical composition is contemplated.

[0242] The term "therapeutically effective amount" of a compound of the present disclosure refers to an amount of a compound of the present disclosure that will elicit a biological or medical response in a subject (e.g., reduction or inhibition of enzyme or protein activity), or improve symptoms, alleviate a condition, slow or delay disease progression, or prevent a disease, etc. In one non-limiting embodiment, the term "therapeutically effective amount" refers to an amount of a compound of the present disclosure that, when administered to a subject, is effective to: (1) at least partially alleviate, inhibit, prevent and / or improve a condition or disorder or disease that (i) is mediated by a kinase (e.g., RET) or (ii) is associated with the activity of a kinase (e.g., RET) or (iii) is characterized by the activity (normal or abnormal) of RET; or (2) reduces or inhibits the activity of RET or (3) reduces or inhibits the expression of RET.

[0243] In another non-limiting embodiment, the term "therapeutically effective amount" refers to an amount of a compound of the present disclosure that is effective to at least partially reduce or inhibit the activity of RET or at least partially reduce or inhibit the expression of RET when the compound of the present disclosure is administered to a cell or tissue or a non-cellular biological material or medium.

[0244] As used herein, the term "subject" refers to an animal. Typically, the animal is a mammal. A subject also refers to, for example, a primate (e.g., a human, male animal, or female animal), a cow, a sheep, a goat, a horse, a dog, a cat, a rabbit, a rat, a mouse, a fish, a bird, etc. In certain embodiments, the subject is a primate. In specific embodiments, the subject is a human.

[0245] As used herein, the terms "inhibit," "inhibition," or "inhibiting" refer to the reduction or suppression of a given condition, activity, effect, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process.

[0246] As used herein, in one embodiment, the terms "treat," "treating," or "treatment" of any disease or disorder refer to ameliorating the disease or disorder (i.e., slowing or preventing or reducing the development of at least one of the disease or its clinical symptoms). In other embodiments, "treat," "treating," or "treatment" refer to alleviating or improving at least one physical parameter (including those that cannot be discerned by the patient). In other embodiments, "treat," "treating," or "treatment" refer to regulating a disease or disorder physically (e.g., stabilization of discernible symptoms), physiologically (e.g., stabilization of a physical parameter), or both physically and physiologically. In other embodiments, "treat," "treating," or "treatment" refer to delaying the development or progression of a disease or disorder.

[0247] As used herein, a subject is "in need of" a treatment if the subject would be expected to benefit biologically, medically, or in quality of life from such treatment.

[0248] As used herein, the terms “a,” “an,” “the” and similar terms used in the context of the disclosure (especially in the context of the claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context.

[0249] All methods described herein can be performed in any suitable order, unless otherwise specified herein or context clearly contradicts. The use of any and all embodiments or exemplary language (e.g., "such as") provided herein is intended only to better illustrate the present disclosure, rather than to limit the scope of the present disclosure otherwise claimed.

[0250] Any asymmetric atom (e.g., carbon, etc.) of one or more compounds of the present disclosure may exist in a racemic or enantiomerically enriched configuration (e.g., (R)-, (S)-, or (R,S)-configuration). In certain embodiments, each asymmetric atom has at least 50% enantiomeric excess, at least 60% enantiomeric excess, at least 70% enantiomeric excess, at least 80% enantiomeric excess, at least 90% enantiomeric excess, at least 95% enantiomeric excess, or at least 99% enantiomeric excess of (R)- or (S)-configuration; that is, for optically active compounds, for example, one enantiomer is typically used to substantially exclude the other enantiomer. Where possible, substituents at atoms having carbon-carbon double bonds may exist in cis-(Z)- or trans-(E)-forms, and unless otherwise indicated, both are included in the present disclosure.

[0251] Thus, as used herein, the compounds of the present disclosure may be in the form of one of the possible isomers, rotamers, atropisomers, or as a mixture thereof (e.g., as substantially pure geometric (cis or trans) isomers, diastereomers, optical isomers (enantiomers), racemates, or mixtures thereof). As used herein, "substantially pure" or "substantially free of other isomers" means that the product contains less than 5% by weight (e.g., less than 2% by weight) of other isomers, calculated by weight relative to the amount of the preferred isomer.

[0252] Any resulting mixtures of isomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric or optical isomers, diastereomers, racemates, for example, by chromatography and / or fractional crystallization.

[0253] Any resulting racemate of the final product or intermediate product can be split into optical antipodes by known methods (e.g., by separating its diastereomeric salt obtained with optically active acid or optically active base, and releasing optically active acidic compound or optically active basic compound). In particular, the basic part can be thus adopted to split the compound of the present disclosure into its optical antipodes, for example, by fractional crystallization with an optically active acid (e.g., tartaric acid, dibenzoyltartaric acid, diacetyltartaric acid, di-O, O'-p-toluoyltartaric acid, mandelic acid, malic acid or camphor-10-sulfonic acid) salt formed. The racemic product can also be split by chiral chromatography (e.g., high pressure liquid chromatography (HPLC) using a chiral adsorbent).

[0254] In addition, the compounds of the present disclosure (including its salt) can also be obtained in the form of its hydrate, or include other solvents for its crystallization. The compounds of the present disclosure can form solvates with pharmaceutically acceptable solvents (including water) inherently or by design; Therefore, the present disclosure is intended to include both solvated forms and non-solvated forms. The term "solvate" refers to a molecular complex of a compound of the present disclosure (including its pharmaceutically acceptable salt) and one or more solvent molecules. Such solvent molecules are those solvent molecules (e.g., water, ethanol, etc.) commonly used in the field of medicine that are known to be harmless to recipients. The term "hydrate" refers to a complex in which the solvent molecule is water.

[0255] Schemes 1-2 illustrate general methods for preparing compounds of the present disclosure and intermediates. Detailed descriptions and synthetic methods are disclosed in the following examples. Those skilled in the art will be able to find other synthetic methods or modify the following methods using conventional chemistry to prepare suitable compounds encompassed by Formula I. Therefore, these methods are equally applicable to the preparation of compounds of other embodiments. Although specific starting materials and reagents are depicted in the scheme and discussed below, other starting materials and reagents can be easily replaced to provide various compounds and / or reaction conditions.

[0256] Solution 1

[0257]

[0258] Compounds of Formula I can be prepared by the general synthetic method illustrated in Scheme 1, wherein R 1 , R 2 , A 1 -A 2 , X, Y 1 -Y 6and n are the same as those defined in Embodiment 1 above. Compounds 1, 2A, 2B, 4, 6 and 9 can be prepared by many methods known to those skilled in the art or can be commercially available. Compound 1 (Z1 and Z2 are Cl, Br, I or OTf independently) can react with compound 2A (P is a protecting group, such as Boc, Cbz or benzyl) under Buchwald reaction conditions of palladium chemistry or react by nucleophilic displacement reaction of Z1 of compound 1 by compound 2A to produce compound 3. The reaction selectivity between Z1 and Z2 can be controlled by placing different groups at Z1 and Z2, or when compound 1 is symmetrical, Z1 and Z2 can be the same. For example, it is possible to start from compound 1 (wherein Z1 is Br, and Z2 is Cl or F). Compound 3 can be converted to boronic acid or pinacol boron ester and bis(pinacolato)diboron using palladium catalyzed chemistry and then subjected to Suzuki reaction with pyrazolo[1,5-a]pyridine 4 (Z3 and Z4 are independently Cl, Br, I or OTf) using palladium catalyzed chemistry to produce compound 5. The reaction selectivity between Z3 and Z4 can be controlled by placing different groups at Z3 and Z4. For example, one can start with compound 4 (where Z3 is OTf and Z4 is Br). Another method is to make Z3 a halogen element and Z4 an OP (P is a protecting group); the latter can be deprotected and converted to a triflate in the next reaction. Suzuki coupling of compound 5 with compound 6 (Z5 is boronic acid or pinacol ester) can be performed to produce compound 7. Alternatively, compound 5 can be converted to boronic acid or pinacol ester and biboronic acid pinacol ester using palladium catalyzed chemistry, and then subjected to Suzuki reaction with compound 6 (Z5 is Cl, Br, I or OTf) using palladium catalyzed chemistry to produce compound 7. Compound 7 is deprotected under appropriate conditions based on the type of protecting group to produce compound 8 (e.g., hydrochloric acid or TFA for Boc; hydrogenolysis for benzyl or CBZ). The coupling reaction of compound 8 with compound 9 (Z6 is -W-CHO, -CO2H, -COCl or -SO2Cl, wherein W is C1-C5 alkylene or C1-C5 haloalkylene) can be carried out under appropriate reaction conditions to produce compounds of formula I. For example, for compound 8 where Z6 is an aldehyde group, the coupling conditions are reductive amination, or for compound 8 where Z6 is -COCl or -SO2Cl, the coupling conditions are under alkaline conditions. Alternatively, compound 5 can be prepared by reaction of compound 1 with compound 4 under similar Suzuki reaction conditions to produce compound 10, and then reaction of compound 10 with compound 2A under Buchwald reaction conditions or nucleophilic displacement reaction conditions as described above.

[0259] There are other alternative methods that can be used to prepare compounds of formula I. The reaction of compound 1 with compound 11 under Buchwald reaction conditions or nucleophilic displacement reaction conditions as described above produces compound 12. Compound 11 can be prepared by the reaction of compound 2B and compound 9 under Buchwald reaction conditions of palladium chemistry or nucleophilic displacement reaction conditions and subsequent deprotection under conditions as described above. The Suzuki coupling of compound 12 and compound 4 using palladium catalyzed chemistry can be carried out as described above to produce compound 13. The conversion of compound 13 to a compound of formula I can be achieved by a Suzuki reaction with compound 6 using palladium catalyzed chemistry as described above. Alternatively, compound 13 can be prepared from compound 5 by a two-step process (wherein the deprotection of compound 5, and the subsequent coupling with compound 9 using conditions from the conversion of compound 7 to a compound of formula I as described above).

[0260] Scheme 2 illustrates the preparation of compounds of Formula IA and Formula IB, wherein R 1 , R 2 , A 1 -A 2 , X, Y 1 , Y 5 and Y 6 , and n are the same as those defined in Embodiment 1 above. Compounds 2A, 4, 6, 9 and 14 can be prepared by many methods known to those skilled in the art or can be commercially obtained. In view of the many methods known for preparing the necessary intermediates, the methods are obvious to those skilled in the art, and therefore these methods are also applicable to the preparation of compounds of other embodiments. All palladium-catalyzed reaction conditions, nucleophilic displacement reactions, deprotection, reductive amination, amine or sulfonamide formation reactions, selective methods and approaches are the same as those described in Scheme 1.

[0261] Solution 2

[0262]

[0263] Thus, the reaction of compound 4 with compound 14 undergoes a Suzuki reaction using similar reaction conditions of palladium chemistry to provide compound 15. The conversion of compound 15 to compound 16 can be achieved under Buchwald reaction conditions of palladium chemistry or by nucleophilic displacement of Z1 of compound 15 of compound 2A. Deprotection of compound 16 produces compound 17. Coupling of compound 17 with compound 9 under similar conditions as described above provides compound 18. Reaction of compound 18 with compound 6 under Suzuki reaction conditions provides compounds of Formula IA and Formula IB. Compound 18 can alternatively be prepared from compound 14. Thus, the conversion of compound 14 to compound 19 is achieved under Buchwald reaction conditions of palladium chemistry or by nucleophilic displacement reaction conditions of compound 2A. Compound 19 undergoes deprotection to provide compound 20, which is subjected to coupling reaction conditions with compound 9 to produce compound 21. Suzuki reaction of compound 21 with compound 4 provides compound 18. Alternatively, compound 18 can be prepared by reacting compound 11 from Scheme 1 above with compound 15 under Buchwald reaction conditions or nucleophilic displacement reaction conditions for palladium chemistry as described above. Compound 21 can also be prepared alternatively by reacting compound 11 with compound 14 under Buchwald reaction conditions or nucleophilic displacement reaction conditions for palladium chemistry as described above. Example

[0264] The following examples illustrate certain embodiments of the present disclosure and how to make and use them. They are not intended to limit the scope of the invention. Those skilled in the art will readily recognize various non-critical parameters and conditions that can be changed or modified to produce substantially the same results. According to one or more of the assays described herein, the following example compounds were found to be inhibitors of RET.

[0265] In the following examples, the following abbreviations are used:

[0266] BINAP 2,2'-Bis(diphenylphosphine)-1,1'-binaphthyl

[0267] BOC tert-Butyloxycarbonyl

[0268] B2(Pin)2 Bis(pinacol)diboron

[0269] BTEAC Benzyltriethylammonium chloride

[0270] CDI Carbonyldiimidazole

[0271] dba dibenzylideneacetone

[0272] DCE 1,2-Dichloroethylene

[0273] DCM Dichloromethane

[0274] DHP Dihydropyran

[0275] DIAD Diisopropyl azodicarboxylate

[0276] DIPEA Diisopropylethylamine

[0277] DMA Dimethylacetamide

[0278] DMAP 4-dimethylaminopyridine

[0279] DMF Dimethylformamide

[0280] DMSO Dimethyl sulfoxide

[0281] dppf 1,1'-Bis(diphenylphosphino)ferrocene

[0282] EDTA Ethylenediaminetetraacetic acid

[0283] EtOAc Ethyl acetate

[0284] EtOH

[0285] HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate

[0286] KHMDS Potassium Hexamethyldisilazane

[0287] LiHMDS Lithium Hexamethyldisilazane

[0288] LG Leaving Group

[0289] MeOH Methanol

[0290] MsCl Methanesulfonyl chloride

[0291] MTBE Methyl tert-butyl ether

[0292] Pd2dba3 Tris(dibenzylideneacetone)palladium

[0293] Pd(dppf)Cl2[1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride

[0294] PE Petroleum Ether

[0295] PG Protecting Group

[0296] PPTS Pyridinium p-toluenesulfonate

[0297] Prep-TLC Preparative Thin Layer Chromatography

[0298] PTSA p-Toluenesulfonic acid

[0299] TBAF Tetra-n-butylammonium fluoride

[0300] TBDMSCl tert-butyldimethylsilyl chloride

[0301] TEA Triethylamine

[0302] TES Triethylsilane

[0303] TFA Trifluoroacetic acid

[0304] Tf trifluoromethanesulfonyl

[0305] Tf2O trifluoromethanesulfonic anhydride

[0306] TLC Thin Layer Chromatography

[0307] THF Tetrahydrofuran

[0308] THP Tetrahydropyran

[0309] TMS Trimethylsilyl

[0310] TosMIC Tosylmethyl isocyanide

[0311] Xantphos 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene

[0312] XPhos 2-Dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl

[0313] Intermediate 1

[0314] 6-Bromo-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane-3-yl)- yl)pyridin-3-yl)pyrazolo

[0315] Preparation of [1,5-a]pyridine-3-carbonitrile

[0316]

[0317] Step 1. 6-Bromo-4-hydroxypyrazolo[1,5-a]pyridine-3-carbonitrile

[0318] To a solution of 6-bromo-4-methoxypyrazolo[1,5-a]pyridine-3-carbonitrile (50 g, 198.4 mmol) in DMA (1 L) was added 50% NaOH (aqueous solution, 23.8 g, 297.6 mmol) and dodecanethiol (60 g, 297.6 mmol). The mixture was stirred at 40 ° C for 3 h, diluted with ice water (4 L), acidified to pH 5-6 by 10% AcOH (aqueous solution), and extracted with EtOAc (2 L × 2). The combined extracts were washed with water (500 mL × 2) and brine (500 mL), dried over Na2SO4, filtered and concentrated to produce the title compound (44 g, yield: 93%).

[0319] Step 2. 6-Bromo-3-cyanopyrazolo[1,5-a]pyridin-4-yl trifluoromethanesulfonate

[0320] To a solution of the product of step 1 above (44 g, 184.8 mmol) in DMA (500 mL) was added DIPEA (48 g, 369.7 mmol). The mixture was cooled in an ice-water bath and a solution of N-phenyl-bis(trifluoromethanesulfonimide) (73 g, 203.3 mmol) was slowly added. After the addition was complete, the mixture was stirred at room temperature for 3 h, diluted with ice water (3.5 L), and stirred for 0.5 h. The formed precipitate was collected by filtration, dissolved in EtOAc (1 L), washed with water (500 mL×3) and brine (500 mL), dried over Na2SO4, filtered and concentrated to produce the title compound (67.9 g, yield: 99%).

[0321] Step 3. 6-Bromo-4-(6-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0322] To a solution of the product of step 2 above (30 g, 81.1 mmol), (6-fluoropyridin-3-yl)boronic acid (11.42 g, 81.1 mmol) and AcOK (15.9 g, 162.1 mmol) in dioxane (300 mL / 60 mL) was added Pd(dppf)Cl2.DCM (1.32 g, 1.62 g) under N2. The mixture was stirred at 35 °C overnight, cooled to room temperature, and diluted with water (1000 mL). The reaction mixture was stirred for 30 min, and the precipitate was collected by filtration. The filter cake was dissolved in DCM / MeOH (10 / 1, 1000 mL), washed with water (500 mL) and brine (500 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel flash column chromatography (DCM / MeOH=10 / 1 to 100 / 1) to produce the title compound (14.35 g, yield: 52%).

[0323] Step 4. 3-(5-(6-bromo-3-cyanopyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-3,6-diazabi Cyclo[3.1.1]heptane-6-carboxylic acid tert-butyl ester

[0324] The product of the above step 3 (7.62g, 24.02mmol), 3,6-diazabicyclo [3.1.1] heptane-6-carboxylic acid tert-butyl ester (5.71g, 28.8mmol) and K2CO3 (6.64g, 48.04mmol) in DMF (100mL) was stirred overnight at 110°C. The mixture was cooled to room temperature and concentrated. The residue was dissolved in EtOAc (500mL), washed with water (150mL×2) and brine (150mL), dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel flash column chromatography (PE / EtOAc=10 / 1 to 2 / 1) to produce the title compound (7.0g, yield: 59%). Step 5. 4-(6-(3,6-diazabicyclo [3.1.1]heptane-3-yl)pyridin-3-yl)-6-bromopyrazolo[1,5-a]pyridine-3-carbonitrile hydrochloride

[0325] To an ice-cooled solution of the product of step 4 above (7.0 g, 14.13 mmol) in DCM / MeOH (4 / 1, 110 mL) was added 4N HCl / dioxane (28 mL). The mixture was stirred at room temperature overnight and then concentrated to dryness to give the crude title compound (7.6, crude yield: 126%).

[0326] Step 6. 6-Bromo-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptyl alkyl-3-yl)pyridin-3-yl)

[0327] Pyrazolo[1,5-a]pyridine-3-carbonitrile

[0328] To the crude product of step 5 above (1.12 g, 1.62 mmol) and 6-methoxynicotinaldehyde (6-methoxynicotinaldehyde) (335 mg, 2.44 mmol) in DCM (20 mL) was added NaBH (OAc) 3 (690 mg, 3.25 mmol). The reaction mixture was stirred at room temperature for 30 min. TEA (492 mg, 4.86 mmol) was added to the reaction mixture. The mixture was stirred at room temperature overnight and quenched with saturated NaHCO 3 aqueous solution (20 mL). The mixture was extracted with DCM (100 mL). The extract was washed with water (50 mL) and brine (50 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated. The residue was purified by silica gel flash column chromatography (MeOH / DCM = 0 to 1 / 30) to produce the title compound (650 mg, yield: 77%).

[0329] Intermediate 2

[0330] 6-Bromo-4-(5-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane-3-yl)- 2-YL)Pyrazin-2-yl)Pyrazolo

[0331] Preparation of [1,5-a]pyridine-3-carbonitrile

[0332]

[0333] Step 1. tert-Butyl 3-(5-chloropyrazin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate

[0334] To a solution of 3,6-diazabicyclo [3.1.1] heptane-6-carboxylic acid tert-butyl ester (1.5g, 10.1mmol) in DMF (30mL) was added K2CO3 (2.78g, 20.1mmol) and 2,5-dichloropyrazine (2.0g, 10.1mmol) in sequence. The mixture was stirred overnight at 110 ° C, cooled to room temperature, and concentrated to dryness. The residue was absorbed in EtOAc (300mL), washed with water (100mL) and brine (100mL), dried over Na2SO4, filtered and concentrated. The residue was purified by flash column chromatography on silica gel (PE / EtOAc=10 / 1 to 5 / 1) to produce the title compound (2.84g, yield: 91%).

[0335] Step 2. 3-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazin-2-yl)-3,6-diazepine Bicyclo[3.1.1]heptane-6-carboxylic acid tert-butyl ester

[0336] To a solution of the product of step 1 above (2.4 g, 7.72 mmol) in dry toluene (10 mL) was added B2pin2 (2.05 g, 8.11 mmol), XPhos (368 mg, 0.772 mmol), [(cinnamyl)PdCl]2 (100 mg, 0.193 mmol) and KOAc (2.27 g, 23 mmol) in sequence. The mixture was stirred at 100 ° C. under nitrogen for 5 h, cooled to room temperature, and concentrated. The residue was used in the next step without any further purification.

[0337] Step 3. 3-(5-(6-bromo-3-cyanopyrazolo[1,5-a]pyridin-4-yl)pyrazin-2-yl)-3,6-diazabi Cyclo[3.1.1]heptane-6-carboxylic acid tert-butyl ester

[0338] The crude product (7.72 mmol) of step 2 above in dioxane (20 mL) and water (4 mL) was added successively to the product of step 2 in the synthesis of the intermediate product (2.85 g, 7.72 mmol), Na2CO3 (1.63 g, 15.3 mmol) and Pd(dppf)Cl2.DCM (630 mg, 0.772 mmol). The mixture was stirred overnight at 40 ° C under nitrogen and filtered. The filtrate was diluted with DCM / MeOH (200 mL), washed with water (100 mL) and brine (100 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel flash column chromatography (PE / EtOAc=6 / 1 to 2 / 1) to produce the title compound (729 mg, yield: 19%).

[0339] Step 4. 4-(5-(3,6-diazabicyclo[3.1.1]heptane-3-yl)pyrazin-2-yl)-6-bromopyrazolo[1,5- a]Pyridine-3-carbonitrile

[0340] At 0 ℃, to the solution of the product (729mg, 1.47mmol) of the above-mentioned step 3 in DCM (18mL) TFA is added.The mixture is stirred at room temperature for 1h, then concentrated to dryness.Use saturated NaCOThe aqueous solution neutralizes the residue, and extracts with DCM / i-PrOH (3 / 1, 60mL×3).Wash the combined extracts with water (50mL) and brine (50mL), at NaSOUpper drying, filter and concentrate to produce title compound (634mg, crude product, quantitative) (it is used for the next step without any further purification).

[0341] Step 4. 6-Bromo-4-(5-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptyl alkyl-3-yl)pyrazin-2-yl)

[0342] Pyrazolo[1,5-a]pyridine-3-carbonitrile

[0343] 6-methoxynicotinaldehyde (155 mg, 1.14 mmol) was added to a solution of the crude product (300 mg, 0.76 mmol) of step 3 above in MeOH (20 mL). The mixture was stirred at room temperature for 30 min, then NaBH3CN (96 mg, 1.52 mmol) and AcOH (0.2 mL, 3.5 mmol) were added. The mixture was stirred at 50 ° C overnight. The reaction mixture was concentrated, and the residue was diluted with water (50 mL), neutralized with saturated NaHCO3 aqueous solution, extracted with DCM / MeOH (10 / 1, 100 mL), washed with water (50 mL) and brine (50 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel flash column chromatography (DCM / MeOH=100 / 1 to 30 / 1) to produce the title compound (283 mg, yield: 72%).

[0344] Example 1

[0345] 6-(5-(2-hydroxypropane-2-yl)pyridin-2-yl)-4-(5-(6-((6-methoxypyridin-3-yl)methyl)-3, 6-Diazabicyclo

[0346] Preparation of [3.1.1] heptane-3-yl)pyrazine-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0347]

[0348] A mixture of intermediate 2 (70 mg, 0.135 mmol), B2Pin2 (36 mg, 0.142 mmol), Pd(dppf)Cl2.DCM (11 mg, 0.0135 mmol) and KOAc (26 mg, 0.27 mmol) in dioxane (1 mL) was stirred at 100° C. for 4 h under nitrogen. The mixture was cooled to room temperature, and 2-(6-bromopyridin-3-yl)propan-2-ol (29 mg, 0.135 mmol), Na2CO3 (29 mg, 0.27 mmol), Pd(dppf)Cl2.DCM (11 mg, 0.0125 mmol), dioxane (1 mL) and water (0.4 mL) were added thereto. The reaction mixture was stirred at 110° C. for 4 h under nitrogen, cooled to room temperature and concentrated. The residue was taken up in DCM / MeOH (10 / 1, 60 mL), washed with water (20 mL) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by reverse phase flash column chromatography (MeOH / H2O=20% to 95%) to produce the title compound (24 mg, yield: 32%). MS (ESI) m / z: 574.4 [M+1] +; 1 H NMR(400MHz,DMSO-d6)δ9.67(s,1H),8.80(s,1H),8.50(d,J=8.7Hz,2H),8.27(s,1H),8.0 7(s,1H),8.02(d,J=9.0Hz,1H),7.93(d,J=8.8Hz,1H),7.67(d,J=8.1Hz,1H),6.83(d,J=8. 7Hz,1H),6.76(d,J=8.3Hz,1H),5.57(s,1H),3.81(s,3H),3.75(d,J=11.7Hz,2H),3.67(d ,J=5.4Hz,2H),3.56(d,J=9.0Hz,2H),3.51(s,2H),2.50(s,1H),1.60(s,1H),1.58(s,6H).

[0349] Example 2

[0350] N-((1R,3S,5s,7s)-2-(5-(3-cyano-6-(5-(2-hydroxypropane-2-yl)pyridin-2-yl)pyrazolo[2-yl]propan ...]pyridin-2-yl)pyrazolo[2- Preparation of [1,5-a]pyridin-4-yl)pyrazine-2-yl)-2-azaadamantan-5-yl)-6-methoxynicotinamide

[0351]

[0352] Step 1. (1R,2S,3R,5S,7S)-4-oxoadamantan-2-ylmethanesulfonate

[0353] To a solution of (1r, 3r, 5r, 7r)-adamantan-2-one (50 g, 333 mmol) in MeSO3H (416 g, 4329 mmol) was added NaN3 (23 g, 351 mmol) in portions at 0°C over a period of 2 hours. The reaction was stirred at room temperature for 3 days. The mixture was quenched with ice water (2 L) and extracted with DCM / isopropanol (3 / 1, 2×3 L). The combined organic layers were washed with brine (1.5 L), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo to produce the title compound (62 g, 62% yield).

[0354] Step 2. Bicyclo[3.3.1]non-6-ene-3-carboxylic acid

[0355] To the solution of the product (62g, 254mmol) of step 1 above in EtOH (600mL) and water (600mL) KOH (43g, 762mmol) was added. The mixture was heated to 110°C overnight. After cooling to room temperature, the mixture was acidified to pH 2 with 1N HCl. After removing most of the ethanol under vacuum, the mixture was extracted with EtOAc (2×2L). The combined organic layers were washed with brine (500mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo to produce the title compound (42g, 99% yield).

[0356] Step 3. Methyl bicyclo[3.3.1]non-6-en-3-ylcarbamate

[0357] To the solution of the product (42g, 253mmol) of the above-mentioned step 2 in toluene (400mL), DPPA (76.5g, 278mmol) and TEA (38.3g, 380mmol) are added. Under a nitrogen atmosphere, the mixture is stirred at 90°C for 2h. After being cooled to 0°C, methanol (400mL) is added to the mixture. The obtained mixture is heated to 100°C overnight. The mixture is concentrated under vacuum, and the residue is absorbed in EtOAc (2L), washed with 1N HCl (500mL), saturated NaHCO3 aqueous solution (500mL) and brine (500mL), at anhydrous Na2SO4, dried, filtered, and concentrated in vacuo to produce the title compound (20g, 41% yield).

[0358] Step 4. (1r,3r,5r,7r)-Methyl 2-azaadamantane-2-carboxylate

[0359] At 0°C, trifluoromethanesulfonic acid (77 g, 512 mmol) was added to a solution of the product of step 3 (20 g, 102.5 mmol) in DCM (200 mL). The mixture was stirred at room temperature overnight, quenched with ice water (300 mL), and extracted with DCM (2 × 500 mL). The combined organic layers were washed with saturated NaHCO aqueous solution (200 mL) and brine (200 mL), dried over anhydrous NaSO, filtered, and concentrated in vacuo to produce the title compound (20 g, 100% yield).

[0360] Step 5. (1r,3r,5r,7r)-2-Azaadamantane hydrochloride

[0361] The product of step 4 above (20 g, 102.5 mmol) was added to 4N HCl / dioxane (200 mL) and concentrated hydrochloric acid (200 mL) at 0° C. The mixture was stirred at 90° C. overnight and concentrated in vacuo to give the title compound (18 g, 100% yield).

[0362] Step 6. (1r,3r,5r,7r)-tert-Butyl 2-azaadamantane-2-carboxylate

[0363] At 0 ℃, to the solution of the product (18g, 103mmol) of the above step 5 in DCM (200mL), TEA (31g, 309mmol) and Boc2O (29g, 134mmol) were added. The mixture was stirred overnight at 0-room temperature. The mixture was diluted with DCM (300mL), washed with water (100mL) and brine (100mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (PE: EtOAc = 50: 1 to 20: 1) to produce the title compound (10g, 41% yield).

[0364] Step 7. (1r,3r,5r,7r)-2-Azaadamantane hydrochloride

[0365] The product of step 6 above (10 g, 102.5 mmol) was added to 4N HCl / dioxane (100 mL) at 0°C. The mixture was stirred at room temperature for 2 h. The mixture was concentrated in vacuo and triturated with hexane: ether (1:1, 50 mL×2) to produce the title compound (4.8 g, 65% yield). LC-MS (m / z): 138.1

[0366] Step 8. (1R,3S,5s,7s)-tert-Butyl 5-hydroxy-2-azaadamantane-2-carboxylate

[0367] The product of step 7 above (4.3 g, 24.7 mmol) was added to concentrated nitric acid (43 mL) and H2SO4 (7.2 mL) at 0°C. The mixture was stirred at 80°C overnight. After cooling to room temperature, the mixture was quenched with ice water (200 mL) and basified with solid Na2CO3. The aqueous layer was washed with DCM. The aqueous layer was diluted with THF (200 mL), cooled to 0°C, and treated with TEA (5 g, 49.4 mmol) and Boc2O (7 g, 32.1 mmol). The resulting mixture was stirred at 0 ~ room temperature overnight and extracted with EtOAc (300 mL x 2). The combined organic layers were washed with water (100 mL) and brine (100 mL), dried over anhydrous Na2SO4, filtered and vacuumed. The residue was purified by silica gel flash column chromatography (PE:EtOAc=8:1 to 2:1) to give the title compound (2.47 g, 40% yield) as a colorless oil. 1 H NMR (400MHz, CDCl3) δ4.46 (s, 2H), 2.29 (s, 1H), 1.79 (s, 2H), 1.73 (t, J = 14.2Hz, 4H) ,1.67(s,1H),1.64(s,1H),1.61(s,2H),1.53(d,J=12.2Hz,2H),1.48–1.40(m,9H).

[0368] Step 9. (1R,3S,5s,7s)-2-Azaadamantan-5-ol TFA salt

[0369] To a solution of the product of step 8 above (2.47 g, 9.76 mmol) in DCM (30 mL) was added TFA (6 mL) at 0°C. The reaction was stirred at 0°C to room temperature for 4 h. The mixture was concentrated in vacuo, and the residue was triturated with hexane: ether (1:1, 20 mL x 2) to give the title compound (2.5 g, 100% yield).

[0370] Step 10. (1R,3S,5s,7s)-2-(5-chloropyrazin-2-yl)-2-azaadamantan-5-ol

[0371] To the solution of the product (5.0g, 20mmol) of the above step 9 in DMF (50mL) was added K2CO3 (8.3g, 60mmol) and 2,5-dichloropyrazine (3.6g, 24mmol) in sequence. The mixture was stirred overnight at 130°C, cooled to room temperature, and concentrated. The residue was absorbed in EtOAc (600mL), washed with water (200mL) and brine (180mL), dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel flash column chromatography (PE / EtOAc=2 / 1 to 1 / 1) to produce the title compound (3.83g, yield: 73%).

[0372] Step 11. N-((1R,3S,5s,7s)-2-(5-chloropyrazin-2-yl)-2-azaadamantan-5-yl)carboxamide

[0373] At 0 ℃, to the product of above-mentioned step 10 (3.6g, 13.5mmol) in concentrated H SO (40mL) solution in add TMSCN (9.1g, 91.7mmol).Mixture is stirred at 60 ℃ and spends the night, is cooled to room temperature, is slowly poured in crushed ice (500g), is alkalized to pH 10 with 5N NaOH, and is extracted with EtOAc (1L×2).The combined extract is washed with brine (500mL), at Na SO Upper drying, is filtered and concentrated.By silica gel flash column chromatography (PE / EtOAc=3 / 1 to 1 / 1) purification of residue to produce title compound (2.62g, yield: 57%).

[0374] Step 12. N-((1R,3S,5s,7s)-2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrrolidone (2-Azaadamantan-5-yl)formamide

[0375] To a solution of the product of step 11 above (584 mg, 2.0 mmol) in dried toluene (10 mL) was added B2pin2 (533 mg, 2.1 mmol), XPhos (95 mg, 0.2 mmol), [(cinnamyl)PdCl]2 (26 mg, 0.05 mmol) and KOAc (588 mg, 6.0 mmol) in sequence. The mixture was stirred at 100 ° C for 4 h under nitrogen. The mixture was cooled to room temperature and concentrated. The residue was used in the next step without any further purification.

[0376] Step 13. N-((1R,3S,5s,7s)-2-(5-(6-bromo-3-cyanopyrazolo[1,5-a]pyridin-4-yl)pyrazine- 2-Azaadamantan-5-yl)formamide

[0377] The product (2.0mmol) of the above step 12 in dioxane (20mL) and water (2mL) was added to the product (740mg, 2.0mmol) in step 2 of intermediate 1, Na2CO3 (424mg, 4.0mmol) and Pd(dppf)Cl2.DCM (163mg, 0.2mmol) in sequence. The mixture was stirred overnight at 40°C under nitrogen. The reaction mixture was filtered, and the filtrate was diluted with EtOAc (120mL), washed with water (30mL) and brine (30mL), dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel flash column chromatography (PE / EtOAc=2 / 1 to DCM / EtOAc=1 / 1) to produce the title compound (540mg, yield: 47%).

[0378] Step 14. N-((1R,3S,5s,7s)-2-(5-(3-cyano-6-(5-(2-hydroxypropan-2-yl)pyridin-2-yl) Pyrazolo[1,5-a]pyridin-4-yl)pyrazin-2-yl)-2-azaadamantan-5-yl)carboxamide

[0379] A mixture of the product of step 13 above (90 mg, 0.189 mmol), B2pin2 (50 mg, 0.198 mmol), KOAc (37 mg, 0.378 mmol) and Pd(dppf)Cl2.DCM (15 mg, 0.0189 mmol) in dioxane (1 mL) was stirred at 100° C. for 4 h under nitrogen. The mixture was cooled to room temperature, and 2-(6-bromopyridin-3-yl)propan-2-ol (41 mg, 0.189 mmol), Pd(dppf)Cl2.DCM (15 mg, 0.0189 mmol), Na2CO3 (40 mg, 0.378 mmol) and dioxane / H2O (1 mL / 0.4 mL) were added thereto. The mixture was stirred at 110° C. for 4 h under nitrogen. After cooling to room temperature, the mixture was diluted with DCM / MeOH (10 / 1, 60 mL), washed with water (20 mL) and brine (20 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by preparative TLC (DCM / MeOH=15 / 1) to produce the title compound (82 mg, yield: 81%).

[0380] Step 15. 4-(5-((1R,3S,5s,7s)-5-amino-2-azaadamantan-2-yl)pyrazin-2-yl)-6-(5- (2-Hydroxypropane-2-yl)pyridin-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0381] To the solution of the product (82 mg, 0.153 mmol) of step 14 above in EtOH (3 mL) was added 2N NaOH (3 mL). The mixture was stirred at 60 ° C for 3 h. After cooling to room temperature, the mixture was diluted with DCM (80 mL), washed with water (20 mL) and brine (20 mL), dried over Na SO, filtered and concentrated to produce the title compound (73 mg, yield: 93%) (which was used in the next step without any further purification).

[0382] Step 16. N-((1R,3S,5s,7s)-2-(5-(3-cyano-6-(5-(2-hydroxypropan-2-yl)pyridin-2-yl) Pyrazolo[1,5-a]pyridin-4-yl)pyrazin-2-yl)-2-azaadamantan-5-yl)-6-methoxynicotinamide

[0383] To a solution of the product of step 15 above (73 mg, 0.144 mmol) in DMF (1 mL) was added 6-methoxynicotinic acid (22 mg, 0.144 mmol), HATU (82 mg, 0.216 mmol)) and DIPEA (56 mg, 0.432 mmol) in sequence. The mixture was stirred at room temperature for 3 h, diluted with EtOAc (60 mL), washed with water (20 mL) and brine (20 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by preparative TLC (DCM / MeOH=15 / 1) to produce the title compound (40 mg, yield: 44%). MS (ESI) m / z: 642.4 [M+1] +; 1H NMR(400MHz,DMSO-d6)δ9.55(s,1H),8.82(s,1H),8.75(s,1H),8.65(s,1H),8.59( s,1H),8.46(d,J=8.8Hz,2H),8.19(d,J=8.2Hz,1H),8.06(d,J=8.7Hz,1H),7.98(d, J=8.2Hz,1H),7.86(s,1H),6.84(d,J=8.7Hz,1H),5.29(s,1H),4.93(s,2H),3.88(s ,3H),2.35–2.24(m,4H),2.21(s,1H),2.15(m,2H),1.84–1.75(m,4H),1.50(s,6H).

[0384] Example 3

[0385] 3-Chloro-N-((1R,5S,6r)-3-(5-(3-cyano-6-(5-(2-hydroxypropane-2-yl)pyridin-2-yl)pyrazole Preparation of 3-azabicyclo[3.1.0]hexane-6-yl)pyridinecarboxamide

[0386]

[0387] Step 1. ((1R,5S,6r)-3-(5-bromopyridin-2-yl)-3-azabicyclo[3.1.0]hexan-6-yl)amino Tert-butyl ester

[0388] To a solution of 5-bromo-2-fluoropyridine (185mg, 0.90mmol) in DMF (5mL), (1R, 5S, 6r) -3- azabicyclo [3.1.0] hexane -6- ylcarbamic acid tert-butyl ester (178mg, 0.9mmol) and K2CO3 (249mg, 1.8mmol) were added. The reaction mixture was stirred overnight at 110°C, cooled to room temperature and concentrated. The residue was dissolved in EtOAc (100mL), washed with H2O (50mL × 2) and brine (50mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (PE / EtOAc=20 / 1 to 4 / 1) to produce the title compound (108mg, yield: 29%).

[0389] Step 2. ((1R,5S,6r)-3-(5-(6-bromo-3-cyanopyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)- tert-Butyl 3-azabicyclo[3.1.0]hexan-6-yl)carbamate

[0390] To a solution of the product of step 1 above (108 mg, 0.305 mmol) in dioxane (1 mL) was added B2Pin2 (81 mg, 0.320 mmol), Pd(dppf)Cl2·DCM (25 mg, 0.0305 mmol) and KOAc (60 mg, 0.61 mmol) in sequence at room temperature. The reaction mixture was purged with nitrogen and stirred at 100°C for 4 h. After cooling to room temperature, the product of step 2 in intermediate 1 (113 mg, 0.305 mmol), Pd(dppf)Cl2·DCM (25 mg, 0.0305 mmol), Na2CO3 (65 mg, 0.61 mmol), dioxane (1 m) and water (1 mL) were added to the reaction mixture. The resulting mixture was purged with nitrogen and stirred at 40°C overnight. The mixture was diluted with DCM / MeOH (10 / 1, 80 mL), washed with H2O (30 mL×2) and brine (30 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by preparative silica gel TLC (PE / EtOAc=1 / 1) to produce the title compound (129 mg, yield: 85%).

[0391] Step 3. ((1R,5S,6r)-3-(5-(3-cyano-6-(5-(2-hydroxypropan-2-yl)pyridin-2-yl)pyrazol- [1,5-a]pyridin-4-yl)

[0392] tert-Butyl pyridin-2-yl)-3-azabicyclo[3.1.0]hexan-6-yl)carbamate

[0393] A mixture of the product of step 2 (129 mg, 0.26 mmol), B2pin2 (69 mg, 0.273 mmol), KOAc (51 mg, 0.52 mmol) and Pd(dppf)Cl2.DCM (21 mg, 0.026 mmol) in dioxane (1 mL) was stirred at 100° C. for 4 h under nitrogen. The mixture was cooled to room temperature, and 2-(6-bromopyridin-3-yl)propan-2-ol (41 mg, 0.189 mmol), Pd(dppf)Cl2.DCM (21 mg, 0.026 mmol), Na2CO3 (55 mg, 0.52 mmol), dioxane / H2O (1 mL / 0.4 mL) were added thereto. The resulting mixture was stirred at 110° C. for 4 h under nitrogen. After cooling to room temperature, the mixture was diluted with DCM / MeOH (10 / 1, 80 mL), washed with water (20 mL) and brine (20 mL), and stirred under N a 2SO4, filtered and concentrated. The residue was purified by C18 reverse phase flash column chromatography (MeOH / H2O) to give the title compound (66 mg, yield: 46%).

[0394] Step 4. 4-(6-((1R,5S,6r)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl)pyridin-3-yl)- 6-(5-(2-Hydroxypropane-2-yl)pyridin-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile trifluoroacetate

[0395] To a solution of the product of step 3 above (66 mg, 0.12 mmol) in DCM (6 mL) was added TFA (2 mL) at 0° C. The mixture was stirred at room temperature for 1 h and concentrated to give the title compound (97 mg, crude), which was used in the next step without any further purification.

[0396] Step 5. 3-Chloro-N-((1R,5S,6r)-3-(5-(3-cyano-6-(5-(2-hydroxypropan-2-yl)pyridine-2-yl)- 1-(4-yl)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-3-azabicyclo[3.1.0]hexane-6-yl)picolinamide

[0397] To a solution of the product of step 4 above (97 mg, 0.12 mmol) in DMF (3 mL) was added 3-chloropicolinic acid (19 mg, 0.12 mmol), HATU (68 mg, 0.18 mmol) and DIPEA (78 mg, 0.6 mmol) in sequence. The mixture was stirred at room temperature for 3 h, diluted with DCM / MeOH (10 / 1, 60 mL), washed with water (20 mL) and brine (20 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by preparative TLC (EtOAc / MeOH=20 / 1) to produce the title compound (43 mg, yield: 61%). MS (ESI) m / z: 591.3 [M+1] +; 1 H NMR (400MHz, DMSO-d6) δ9.51(s,1H),8.81(s,1H),8.72(s,1H),8.47(s,1H),8.40(d,J=4. 6Hz,1H),8.33(s,1H),8.16(d,J=8.2Hz,1H),8.09(s,1H),7.97(d,J=8.3Hz,1H),7.89(d, J=8.1Hz,1H),7.77(d,J=8.7Hz,1H),7.42(dd,J=8.2,4.6Hz,1H),6.50(d,J=8.7Hz,1H),5 .29(s,1H),3.81–3.58(m,4H),2.96(t,J=7.0Hz,1H),2.11(d,J=7.0Hz,2H),1.49(s,6H).

[0398] Example 4

[0399] 6-(5-(2-hydroxypropane-2-yl)-1-methyl-1H-pyrazol-3-yl)-4-(6-(6-((6-methoxypyridine-3- 1-(4-(2-(4-(2-(4-nitro-1-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile preparation

[0400]

[0401] A mixture of intermediate 1 (100 mg, 0.193 mmol), B2Pin2 (49 mg, 0.193 mmol), Pd(dppf)Cl2.DCM (18.8 mg, 0.0193 mmol) and KOAc (56.7 mg, 0.58 mmol) in dioxane (1 mL) was stirred at 100 °C for 3 h under N2. After cooling to room temperature, 2-(3-bromo-1-methyl-1H-pyrazol-5-yl)propan-2-ol (29 mg, 0.135 mmol), Na2CO3 (40 mg, 0.38 mmol) and water (0.2 mL) were added to the mixture. The reaction mixture was stirred at 100 °C for 3 h under N2 and cooled to room temperature. The mixture was concentrated. The residue was taken up in DCM / MeOH (10 / 1, 20 mL), washed with water (10 mL) and brine (10 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by reverse phase flash column chromatography (MeOH / H2O=20% to 95%) to give the title compound (22 mg, yield: 28%). MS (ESI) m / z: 576.6 [M+1] +; 1 HNMR(400MHz, CDCl3)δ8.82(s,1H),8.39(s,1H),8.28(s,1H),8.11(s,1H),7.81(d,J=8.7Hz,1H),7.76(s,1H),7.65(s,1H),6.75– 6.66(m,2H),6.40(s,1H),4.14(s,3H),3.92(s,3H),3.88–3.75(m,4H),3.68–3.56(m,4H),2.71(s,1H),1.70(s,6H),1.66(d,1H).

[0402] Example 5

[0403] 3-Chloro-N-(((1R,5S,6s)-3-(5-(3-cyano-6-(5-(2-hydroxypropane-2-yl)pyridin-2-yl)pyrazole 4-((1,5-a]pyridin-4-yl)

[0404] Preparation of pyridin-2-yl)-3-azabicyclo[3.1.0]hexane-6-yl)methyl)picolinamide

[0405]

[0406] Step 1. 3-Benzyl 6-ethyl (1R, 5S, 6r)-3-azabicyclo [3.1.0] hexane-3,6-dicarboxylate and 3-benzyl 6-ethyl (1R,5S,6s)-3-azabicyclo[3.1.0]hexane-3,6-dicarboxylate

[0407] To 2,5-dihydro-1H-pyrrole-1-carboxylic acid benzyl ester (5.0g, 24.6mmol) and Rh2(OAc)4(500mg, 1.13mmol) in DCE (50mL) heated to 80°C in a period of 4h, a solution of ethyl 2-diazoacetate (14g, 123mmol) in DCE (50mL) was added dropwise. After the addition was completed, the mixture was stirred at 80°C overnight. After cooling, the mixture was concentrated in vacuo. The residue was purified by silica gel flash column chromatography (PE / EtOAc=20 / 1 to 4 / 1) to produce (1R, 5S, 6r)-isomer (upper spot of TLC, 3.1g, yield: 43%) and (1R, 5S, 6s)-isomer (lower spot of TLC, 1.6g, yield: 22%).

[0408] Step 2. (1R,5S,6r)-6-(Hydroxymethyl)-3-azabicyclo[3.1.0]hexane-3-carboxylic acid benzyl ester

[0409] At 0 ° C, BH3 / THF (1N, 18 mL, 18 mmol) was added dropwise to the solution of (1R, 5S, 6r)-isomer in THF (25 mL) of the above step 1. After the addition was completed, the mixture was heated to 70 ° C and stirred for 2 h. The mixture was concentrated in vacuo, and the residue was absorbed in DCM (50 mL) and brine (30 mL), and the layers were separated. The aqueous layer was acidified to pH 5 with 1N HCl and extracted with DCM (50 mL×2). The combined organic layers were dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was purified by silica gel flash column chromatography (PE / EtOAc=1 / 1) to produce the title compound (1.18 g, yield: 47%).

[0410] Step 3. (1R,5S,6r)-6-((bis(tert-butoxycarbonyl)amino)methyl)-3-azabicyclo[3.1.0]hexane Benzyl 3-alkanecarboxylate

[0411] Under N2 at 0 ℃, to the product of step 2 above (1.13g, 4.57mmol), di-tert-butyl iminodicarboxylate (1.09g, 5.03mmol) and PPh3 (1.56g, 5.94mmol) in THF (20mL) solution, DEAD (1.03g, 5.94mmol) was added dropwise. The mixture was allowed to warm to room temperature, heated to 50 ℃, and stirred overnight. The mixture was extracted with EtOAc (100mL). The organic layer was washed with H2O (30mL) and brine (30mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel flash column chromatography (PE / EtOAc=12 / 1 to 8 / 1) to produce the title compound (900mg, 42%).

[0412] Step 4. (((1R,5S,6r)-3-azabicyclo[3.1.0]hexan-6-yl)methyl)(tert-butoxycarbonyl)amino Tert-Butyl Formate

[0413] To a solution of the product of step 3 above (900 mg, 2.02 mmol) in MeOH (15 mL) was added Pd(OH)2 / C (100 mg, 20% on carbon, about 50% H2O). The mixture was stirred on a hydrogen balloon at room temperature for 1.5 h. The mixture was filtered and the filtrate was concentrated to give the title compound (616 mg, yield: 98%).

[0414] Step 5. N-(tert-Butyloxycarbonyl)-N-(((1R,5S,6r)-3-(5-bromopyridin-2-yl)-3-azabicyclo tert-Butyl [3.1.0]hexane-6-yl)methyl)carbamate

[0415] The product of step 4 above (560 mg, 1.79 mmol), 5-bromo-2-fluoropyridine (316 mg, 1.79 mmol) and KCO (494 mg, 3.58 mmol) were stirred overnight at 100 ° C. After cooling to room temperature, the mixture was concentrated in vacuo. The residue was purified by silica gel flash column chromatography (PE / EtOAc=30 / 1 to 15 / 1) to produce the title compound (550 mg, yield: 60%).

[0416] Step 6. (((1R,5S,6r)-3-(5-(6-bromo-3-cyanopyrazolo[1,5-a]pyridin-4-yl)pyridine-2-yl) tert-Butyl)-3-azabicyclo[3.1.0]hexane-6-yl)methyl)(tert-butoxycarbonyl)carbamate

[0417] A solution of the product of step 5 above (381 mg, 0.813 mmol), B2Pin2 (217 mg, 0.854 mmol), Pd(dppf)Cl2.DCM (66 mg, 0.0813 mmol) and KOAc (160 mg, 1.626 mmol) in dioxane (10 mL) was stirred at 100° C. for 4 h under nitrogen. After cooling to room temperature, the product of step 2 in intermediate 1 (301 mg, 0.813 mmol), Na2CO3 (172 mg, 1.626 mmol), Pd(dppf)Cl2.DCM (66 mg, 0.0813 mmol) and dioxane / H2O (5 mL / 3 mL) were added to the mixture. The reaction mixture was stirred at 40°C for 8h, cooled to room temperature, diluted with DCM / MeOH (10 / 1, 120mL), washed with H2O (50mL) and brine (50mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (PE / EtOAc=10 / 1 to 3 / 1) to produce the title compound (332mg, yield: 53%).

[0418] Step 7. N-(tert-Butyloxycarbonyl)-N-(((1R,5S,6s)-3-(5-(3-cyano-6-(5-(2-hydroxypropane- 2-yl)pyridin-2-yl)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-3-azabicyclo[3.1.0]hexan-6-yl) tert-Butyl methyl)carbamate

[0419] A mixture of the product of step 6 (160 mg, 0.263 mmol), B2pin2 (60 mg, 0.276 mmol), KOAc (52 mg, 0.526 mmol) and Pd(dppf)Cl2.DCM (21 mg, 0.0263 mmol) in dioxane (3 mL) was stirred at 100° C. for 4 h under nitrogen. The mixture was cooled to room temperature, and 2-(6-bromopyridin-3-yl)propan-2-ol (57 mg, 0.263 mmol), Pd(dppf)Cl2.DCM (21 mg, 0.0263 mmol), Na2CO3 (56 mg, 0.526 mmol) and dioxane / H2O (1 mL / 0.4 mL) were added thereto. The resulting mixture was stirred at 110° C. for 4 h under nitrogen. After cooling to room temperature, the mixture was diluted with DCM / MeOH (10 / 1, 100 mL), washed with water (20 mL) and brine (20 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by preparative TLC (DCM / MeOH=20 / 1) to produce the title compound (55 mg, yield: 31%).

[0420] Step 8. 4-(6-((1R,5S,6s)-6-(aminomethyl)-3-azabicyclo[3.1.0]hexan-3-yl)pyridine- 3-yl)-6-(5-(2-hydroxypropane-2-yl)pyridin-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0421] To a solution of the product of step 7 above (55 mg, 0.083 mmol) in DCM (6 mL) was added TFA (2 mL) at 0° C. The mixture was stirred at room temperature for 1 h and concentrated to give the title compound (90 mg, crude), which was used in the next step without any further purification.

[0422] Step 9. 3-Chloro-N-(((1R,5S,6s)-3-(5-(3-cyano-6-(5-(2-hydroxypropan-2-yl)pyridine-2-yl)pyridine 1-(4-yl)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-3-azabicyclo[3.1.0]hexane-6-yl)methyl)picolino[1,5-a]pyridin-4-yl)pyridin-2-yl) amine

[0423] To a solution of the product of step 8 above (90 mg, 0.083 mmol) in DMF (3 mL) was added 3-chloropicolinic acid (13 mg, 0.083 mmol), HATU (47 mg, 0.125 mmol) and DIPEA (53 mg, 0.415 mmol) in sequence. The mixture was stirred at room temperature for 3 h and purified by reverse phase column flash chromatography (H2O / MeOH=80 / 20 to 10 / 90) to produce the title compound (31 mg, yield: 63%). MS (ESI) m / z: 605.4 [M+1] +; 1H NMR (400MHz, DMSO-d6) δ9.51(s,1H),8.80(s,1H),8.76(t,J=5.5Hz,1H),8.73(s,1H),8.55(d,J=4. 5Hz,1H),8.35(s,1H),8.16(d,J=8.3Hz,1H),8.13(s,1H),8.03(d,J=8.2Hz,1H),7.96(d,J=8.3Hz,1 H),7.79(d,J=8.7Hz,1H),7.53(dd,J=8.1,4.6Hz,1H),6.59(d,J=8.7Hz,1H),5.29(s,1H),3.74(d, J=10.5Hz,2H),3.45(d,J=8.9Hz,2H),3.27(t,J=5.4Hz,2H),1.75(s,2H),1.49(s,6H),0.93(s,1H).

[0424] Example 6

[0425] 3-Chloro-N-((3aR,5s,6aS)-2-(5-(3-cyano-6-(5-(2-hydroxypropane-2-yl)pyridin-2-yl)pyridine Oxalo[1,5-a]pyridin-4-yl)

[0426] Preparation of pyrazine-2-yl)-5-methyloctahydrocyclopentane [c] pyrrol-5-yl) picolinamide

[0427]

[0428] Step 1. Tert-butyl (3aR,5r,6aS)-5-hydroxy-5-methylhexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate ester

[0429] Methylmagnesium bromide (1.0 N, 25 mmol) was added to a solution of (3aR, 6aS)-5-oxohexahydrocyclopenta[c]pyrrole-2(1H)-carboxylic acid tert-butyl ester (2.25 g, 10 mmol) in dry toluene (25 mL) at -30 °C. The mixture was stirred at -30 °C for 2 h. The reaction was quenched by dropwise addition of MeOH (2 mL) and HCl (6 N, 10 mL) at -30 °C. The mixture was diluted with EtOAc (100 mL), washed with H2O (30 × 2 mL) and brine (30 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel flash column chromatography (PE / EtOAc=4 / 1-1 / 1) to produce the title compound (2.0 g, yield: 83%).

[0430] Step 2. (3aR,5r,6aS)-5-Methyloctahydrocyclopenta[c]pyrrol-5-ol hydrochloride

[0431] A solution of the product of step 1 above (1.5 g, 6.22 mmol) in HCl / MeOH (4N, 10 mL) was stirred for 2 h at 40° C. The reaction mixture was concentrated and dried in vacuo to give the crude title compound (quantitative).

[0432] Step 3. (3aR,5r,6aS)-2-(5-chloropyrazin-2-yl)-5-methyloctahydrocyclopenta[c]pyrrol-5-ol

[0433] 2,5-dichloropyrazine (0.8 g, 4.5 mmol) was added to a solution of the product (610 mg, 4.1 mmol) and K2CO3 (1.7 g, 12.3 mmol) of step 2 above in DMF (5 mL). The mixture was stirred at 110 ° C for 2 h. After cooling to room temperature, the mixture was diluted with EtOAc (100 mL), washed with H2O (30 mL × 2) and brine (30 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (PE / EtOAc=4 / 1 to 1 / 1) to produce the title compound (630 mg, yield: 61%).

[0434] Step 4. N-((3aR,5s,6aS)-2-(5-chloropyrazin-2-yl)-5-methyloctahydrocyclopenta[c]pyrrol-5-yl) Formamide

[0435] At 0 ℃, to the product of above-mentioned step 3 (200mg, 0.79mmol) and TMSCN (234mg, 2.36mmol) solution in HOAc (0.5mL) add concentrated H2SO4 (0.4mL).The mixture is stirred at room temperature for 2h.Quench the reaction with ice, alkalize to pH 8-9 with NaOH aqueous solution (5N), and extract with DCM (50mL×3).Wash the combined extract with H2O (30mL×2) and brine (30mL), dry on anhydrous Na2SO4, filter and concentrate in vacuo.Purify the residue by preparative TLC (PE / EtOAc=1 / 1 to EtOAc) to produce title compound (215mg, yield: 97%).

[0436] Step 5. N-((3aR,5s,6aS)-5-methyl-2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2- yl)pyrazin-2-yl)octahydrocyclopentane[c]pyrrol-5-yl)carboxamide

[0437] To a solution of the product of step 4 above (651 mg, 2.32 mmol) in dried toluene (10 mL) was added B2pin2 (609 mg, 2.4 mmol), XPhos (95 mg, 0.2 mmol), [(cinnamyl)PdCl]2 (26 mg, 0.05 mmol) and KOAc (588 mg, 6.0 mmol) in sequence. The mixture was stirred at 100 ° C for 4 h under nitrogen, cooled to room temperature, and concentrated. The residue was used in the next step without any further purification.

[0438] Step 6. N-((3aR,5s,6aS)-2-(5-(6-bromo-3-cyanopyrazolo[1,5-a]pyridin-4-yl)pyrazine-2-yl)- (c]pyrrol-5-yl)-5-methyloctahydrocyclopentanecarboxamide

[0439] The product of step 5 (2.0 mmol) in dioxane (10 mL) and water (2 mL) was added to the product of step 2 in intermediate 1 (858 mg, 2.32 mmol), Na2CO3 (492 mg, 4.64 mmol) and Pd(dppf)Cl2.DCM (109 mg, 0.232 mmol) in sequence. The mixture was stirred at 40°C overnight under nitrogen, cooled to room temperature, diluted with DCM / MeOH (10 / 1, 200 mL), washed with water (50 mL) and brine (50 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by preparative TLC (PE / EtOAc=1 / 4) to produce the title compound (153 mg, yield: 15%).

[0440] Step 7. N-((3aR,5s,6aS)-2-(5-(3-cyano-6-(5-(2-hydroxypropan-2-yl)pyridin-2-yl)pyrrolidone (oxazolo[1,5-a]pyridin-4-yl)pyrazin-2-yl)-5-methyloctahydrocyclopenta[c]pyrrol-5-yl)carboxamide

[0441] A mixture of the product of step 6 above (153 mg, 0.328 mmol), B2pin2 (87 mg, 0.344 mmol), KOAc (64 mg, 0.656 mmol) and Pd(dppf)Cl2.DCM (27 mg, 0.0328 mmol) in dioxane (2 mL) was stirred at 100° C. for 4 h under nitrogen. The mixture was cooled to room temperature, and 2-(6-bromopyridin-3-yl)propan-2-ol (71 mg, 0.328 mmol), Pd(dppf)Cl2.DCM (27 mg, 0.0328 mmol), Na2CO3 (70 mg, 0.656 mmol) and dioxane / H2O (3 mL / 1 mL) were added thereto. The mixture was stirred at 110° C. for 4 h under nitrogen. After cooling to room temperature, the mixture was diluted with DCM / MeOH (10 / 1, 60 mL), washed with water (20 mL) and brine (20 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by preparative TLC (DCM / MeOH=20 / 1) to produce the title compound (53 mg, yield: 31%).

[0442] Step 8. 4-(5-((3aR,5s,6aS)-5-amino-5-methylhexahydrocyclopenta[c]pyrrol-2(1H)-yl) Pyrazin-2-yl)-6-(5-(2-hydroxypropane-2-yl)pyridin-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

[0443] To the solution of the product (53 mg, 0.101 mmol) of the above-mentioned step 7 in EtOH (2 mL) was added 2N NaOH (2 mL). The mixture was stirred at 60 ° C for 3 h. After cooling to room temperature, the mixture was diluted with DCM / IPA (3 / 1, 80 mL), washed with water (20 mL) and brine (20 mL), and dried over Na SO, filtered and concentrated to produce the title compound (50 mg, crude product) (which was used in the next step without any further purification).

[0444] Step 9. 3-Chloro-N-((3aR,5s,6aS)-2-(5-(3-cyano-6-(5-(2-hydroxypropan-2-yl)pyridine-2-yl)- yl)pyrazolo[1,5-a]pyridin-4-yl)pyrazin-2-yl)-5-methyloctahydrocyclopenta[c]pyrrol-5-yl)picolinamide

[0445] To a solution of the product of step 8 above (50 mg, ~0.101 mmol) in DMF (1 mL) was added 3-chloropicolinic acid (16 mg, 0.101 mmol), HATU (58 mg, 0.152 mmol) and DIPEA (39 mg, 0.303 mmol) in sequence. The mixture was purified by reverse phase flash column chromatography (MeOH / H2O=5%~95%) to give the title compound (30 mg, yield: 48%). MS (ESI) m / z: 634.4 [M+1]+; 1 H NMR (400MHz, DMSO-d6) δ9.55(s,1H),8.82(s,1H),8.74(s,1H),8.62(d,J=8.2H z,1H),8.54–8.47(m,1H),8.42(s,1H),8.29(s,1H),8.16(t,J=12.8Hz,2H),8. 03–7.92(m,2H),7.48(m,1H),5.30(s,1H),3.75–3.61(m,2H),3.55(d,J=10.7H z,2H),2.96(m,2H),2.67(m,2H),1.52(s,3H),1.50(s,6H),1.48–1.42(m,2H).

[0446] Table 1 lists the examples prepared according to the processes described in Examples 1-4 by using the corresponding intermediates and reagents under appropriate conditions that can be achieved by those skilled in the art.

[0447]

[0448]

[0449]

[0450]

[0451]

[0452]

[0453]

[0454]

[0455]

[0456]

[0457]

[0458]

[0459]

[0460]

[0461] Enzyme assay

[0462] RET kinase assay

[0463] The ATP concentration of the test compound at Km was determined by mobility shift. The assay used human RET kinase (Carna08-159). The test compound was prepared and diluted to 50× of the final test concentration in 3-fold serial dilution in DMSO. Then, the compound was further diluted to 5× with kinase reaction buffer (50mM HEPES pH 7.5, 0.0015% Brij-35). The enzyme reaction for compound testing was carried out in a white 384-well polypropylene plate (Corning 3573) with a total reaction volume of 25μl, containing 7nM RET, 3μM peptide substrate FAM-P2 (GL Biochem 112394) and 23μM ATP (Sigma A7699-1G). The assay began with loading RET diluted in kinase reaction buffer into the well, and then adding an equal volume of 5× compound to incubate at room temperature for 15min for pretreatment. The enzyme reaction was started by adding a mixture of substrate and ATP prepared in kinase reaction buffer. After incubation at 28°C for 1 hour, 25 μl of stop buffer (a mixture of 100 mM HEPES pH 7.5 buffer, 0.015% Brij-35, 50 mM EDTA, and 0.2% coating reagent 3 (Cliper Lifesciences)) was added. After incubation at room temperature for 30 minutes, the plate was read in Caliper. The percentage of control was calculated as the percentage of treated compound relative to the treated 2% DMSO vehicle. Dose-response curves were generated and IC was calculated by nonlinear sigmoidal curve fitting using XLFit. 50 value.

[0464] The IC values ​​of RET biochemical activities of the examples disclosed herein are listed in Table 2. 50 Value (nM).

[0465] KDR kinase assay

[0466] The ATP concentration of the test compound at Km was determined by mobility shift. The assay used human KDR kinase (Carna08-191). The test compound was prepared and diluted to 50× of the final test concentration in 3-fold serial dilution in DMSO. Then, the compound was further diluted to 5× with kinase reaction buffer (50mM HEPES pH 7.5, 0.0015% Brij-35). The enzyme reaction for compound testing was carried out in a white 384-well polypropylene plate (Corning 3573) with a total reaction volume of 25μl, containing 1.2nM KDR, 3μM peptide substrate FAM-P22 (GL Biochem112393) and 92μM ATP (Sigma A7699-1G). The assay began with loading RET diluted in kinase reaction buffer into the well, and then adding an equal volume of 5× compound to incubate at room temperature for 15min for pretreatment. The enzyme reaction was started by adding a mixture of substrate and ATP prepared in kinase reaction buffer. After incubation at 28°C for 1 hour, 25 μl of stop buffer (a mixture of 100 mM HEPES pH 7.5 buffer, 0.015% Brij-35, 50 mM EDTA, and 0.2% coating reagent 3 (Cliper Lifesciences)) was added. After incubation at room temperature for 30 minutes, the plate was read in Caliper. The percentage of control was calculated as the percentage of treated compound relative to the treated 2% DMSO vehicle. Dose-response curves were generated and IC was calculated by nonlinear sigmoidal curve fitting using XLFit. 50 .

[0467] The IC values ​​of KDR biochemical activities of the examples disclosed herein are listed in Table 2. 50 Value (nM).

[0468] Aurora B kinase assay

[0469] The ATP concentration of the test compound at Km was determined by mobility shift. The assay used human Aurora kinase B (Carna05-102). The test compound was prepared and diluted to 50× of the final test concentration in 3-fold serial dilution in DMSO. Then, the compound was further diluted to 5× with kinase reaction buffer (50mM HEPES pH 7.5, 0.0015% Brij-35). The enzyme reaction for compound testing was carried out in a white 384-well polypropylene plate (Corning 3573) with a total reaction volume of 25 μl, 9nM Aurora kinase B, 3 μM peptide substrate FAM-P21 (GLBiochem116370) and 15 μM ATP (Sigma A7699-1G). The assay started with loading the Aurora kinase B diluted in the kinase reaction buffer into the well, and then adding an equal volume of 5× compounds to incubate at room temperature for 15min for pretreatment. The enzyme reaction was started by adding a mixture of substrate and ATP prepared in the kinase reaction buffer. After incubation at 28°C for 1 hour, 25 μl of stop buffer (a mixture of 100 mM HEPES pH 7.5 buffer, 0.015% Brij-35, 50 mM EDTA, and 0.2% coating reagent 3 (Cliper Lifesciences)) was added. After incubation at room temperature for 30 minutes, the plate was read in Caliper. The percentage of control was calculated as the percentage of treated compound relative to the treated 2% DMSO vehicle. Dose-response curves were generated and IC was calculated by nonlinear sigmoidal curve fitting using XLFit. 50 value.

[0470] The IC values ​​of the biochemical activities of Aurora kinase B of the examples disclosed herein are listed in Table 2. 50 Value (nM).

[0471] Cell assay

[0472] TT cell proliferation assay

[0473] The inhibition of RET by the compounds disclosed herein was tested by a cancer cell proliferation assay commonly known as the MTT assay. In this assay, a complete medium was prepared by adding 10% fetal bovine serum to RPMI-1640 medium (Life technology). TT cells were added to each of 88 wells of a 96-well plate at a seeding density of 6000 cells / well / 90 μL. Cells were allowed to attach to the plate by incubation at 37 ° C for 24 hours. The compound was dissolved in DMSO (SIGMA). A solution of the test compound was prepared in complete medium by serial dilution to obtain the following concentrations: 50 μM, 15 μM, 5 μM, 1.5 μM, 0.5 μM, 0.15 μM, 0.05 μM, 0.015 μM and 0.005 μM. The test compound solution (10 μL) was added to each of 80 wells containing cells. The final concentrations of the compounds are as follows: 5 μM, 1.5 μM, 0.5 μM, 0.15 μM, 0.05 μM, 0.015 μM, 0.005 μM, 0.0015 μM and 0.0005 μM. The final concentration of DMSO is 0.5%. Complete medium (containing 0.5% DMSO) is added only to the remaining 8 wells containing cells to form a control group in order to measure maximum proliferation. Complete medium is added to the remaining 8 empty wells to form a blank control group in order to measure background. The plate is incubated at 37 ° C for 8 days. 10 μL WST-8 solution (DOJINDO, Cell Counting KIT-8) is added to each well. The plate is further incubated at 37 ° C for 5 hours, and then the absorbance is read at 450nM using a microplate reader. IC is calculated using GraphPad Prism 50 .

[0474] BAF3-KIF5B-RET, Ba / F3-KIF5B-RET-G810R, Ba / F3-TEL-RET-M918T and Ba / F3- KIF5B-RET-V804M cell proliferation assay

[0475] The inhibition of RET by the cancer cell proliferation assay commonly known as CellTiter-Glo was tested by the compounds disclosed herein. In this assay, 10% fetal bovine serum was added to the RPMI-1640 culture medium (Life technology) of RET-driven cancer cells (BAF3-FIF5B-RET, Ba / F3-KIF5B-RET-G810R, Ba / F3-TEL-RET-M918T or Ba / F3-KIF5B-RET-V804M) to prepare complete culture medium. The cells of the RET-driven type were added to each of the 88 wells of a 96-well plate at a seeding density of 2000 cells / well / 95 μL. Cells were allowed to attach to the plate by incubation at 37°C for 24 hours. The compound was dissolved in DMSO (SIGMA). The solution of test compound is prepared in complete medium by serial dilution to obtain the following concentrations: 20 μM, 6.67 μM, 2.22 μM, 0.74 μM, 0.25 μM, 0.082 μM, 0.027 μM, 0.0091 μM and 0.0030 μM. Test compound solution (5 μL) is added to each of 80 wells containing cells. The final concentration of compound is as follows: 1 μM, 0.33 μM, 0.11 μM, 0.037 μM, 0.012 μM, 0.0041 μM, 0.0014 μM, 0.00046 μM and 0.00015 μM. The final concentration of DMSO is 0.1%. Only complete medium (containing 0.1% DMSO) is added to 8 remaining wells containing cells to form a control group in order to measure maximum proliferation. Complete medium is added to the remaining 8 empty wells to form a blank control group in order to measure background. The plates were incubated at 37°C for 72 hours. 50 μL Reagents were added to each well. Contents were mixed for 2 minutes on an orbital shaker to induce cell lysis. Incubated at room temperature for 10 minutes to stabilize the luminescent signal. Luminescence was recorded on Paradigm. Cell viability (CV%) was calculated relative to vehicle (DMSO) treated control wells. IC was calculated using GraphPad Prism 50 .

[0476] The IC values ​​of the disclosed compounds for growth inhibition in RET-driven cells are listed in Tables 2 and 3. 50 Value (nM).

[0477] BAF3 cell proliferation assay

[0478] The compounds disclosed herein were tested for their effects on BAF3 without REF drive by CellTiter-Glo assay. Cell proliferationInhibition of. In this assay, a complete medium for BAF3 cells was prepared by adding 10% fetal bovine serum and 1ng / ml IL-3 to RPMI-1640 medium (Life technology). BAF3 cells were added to each of 88 wells of a 96-well plate at a seeding density of 2000 cells / well / 95 μL. Cells were allowed to attach to the plate by incubation at 37°C for 24 hours. The compound was dissolved in DMSO (SIGMA). A solution of the test compound was prepared in complete medium by serial dilution to obtain the following concentrations: 200 μM, 66.7 μM, 22.2 μM, 7.4 μM, 2.5 μM, 0.82 μM, 0.27 μM, 0.091 μM and 0.0030 μM. The test compound solution (5 μL) was added to each of 80 wells containing cells. The final concentrations of the compounds are as follows: 10 μM, 3.33 μM, 1.11 μM, 0.37 μM, 0.12 μM, 0.041 μM, 0.014 μM, 0.0046 μM and 0.0015 μM. The final concentration of DMSO is 0.1%. Complete medium (containing 0.1% DMSO) is added only to the 8 remaining wells containing cells to form a control group for measuring maximum proliferation. Complete medium is added to the remaining 8 empty wells to form a blank control group for measuring background. The plates are incubated at 37°C for 72 hours. 50 μL Reagents were added to each well. The contents were mixed on an orbital shaker for 2 minutes to induce cell lysis and then incubated at room temperature for 10 minutes to stabilize the luminescent signal. Luminescence was recorded on Paradigm. Cell viability (CV%) was calculated relative to control wells treated with vehicle (DMSO). IC was calculated using GraphPad Prism 50 .

[0479] Tables 2 and 3 list the IC values ​​of the disclosed compounds for growth inhibition in BAF3 cells. 50 Value (nM).

[0480] Table 2

[0481]

[0482]

[0483] Table 3

[0484]

[0485]

Claims

1. Compounds of formula I: and / or a stereoisomer, a stable isotope or a pharmaceutically acceptable salt or solvate of the compound, wherein: A 1 is a cyclic group selected from phenyl and 5- to 6-membered heteroaryl, wherein the 5- to 6-membered heteroaryl contains 1-2 heteroatoms independently selected from N, O and S as ring members, and wherein the cyclic group is optionally substituted by 1-3 groups independently selected from halogen elements, CN, C1-C4 alkyl and C1-C4 haloalkyl; A 2 is a group selected from the following: The bond marked with an asterisk * represents the L of the connecting formula I 2 Keys; L 1 is a group selected from the following: Where R 3 and R 4 Each is independently selected from H and C1-C6 alkyl, wherein the C1-C6 alkyl is optionally substituted by 1-3 groups independently selected from CN, halogen, OH and C1-C6 alkoxy; or wherein R 3 and R 4 Taken together, they form a group selected from the group consisting of a carbonyl group, a 3- to 6-membered cycloalkyl group, and a 5- to 6-membered heterocyclic ring containing 1-2 heteroatoms independently selected from N, O and S as ring members; L 2 is a group selected from the following: CO, SO 1-2 , C1-C6 alkylene and C1-C6 haloalkylene; R 1 Selected from -CN, ethynyl, halogen, -CF3, -CH3, -CH2CH3, cyclopropyl, -CH2CN and -CH(CN)CH3; Each R 2 are independently selected from halogen, -OR 5 、-N(R 5 )2, -CN, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -OC(O)R 5 、-CO2R 5 、-C(O)N(R 5 )2, -C(=NR 6 )N(R 5 )2. -C(O)R 5 、-S(O) 0-2 R 7 、-S(O)(=NR 6 )R 7 、-S(O) 1-2 N(R 5 )2、-N(R 5 )C(O)R 7 、-N(R 5 )C(=NR 6 )R 7 、-N(R 5 )S(O) 1-2 R 7 、-N(R 5 )C(O)N(R 5 )2、-N(R 5 )C(=NR 6 )N(R 5 )2、-N(R 5 )S(O) 1-2 N(R 5 )2 and -N(R 5 )CO2R 7 ,in: Each R 5 independently selected from H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 haloalkyl, aryl, saturated and unsaturated 4-7 membered heterocyclyl containing 1-2 heteroatoms selected from N, O and S as ring members, and heteroaryl containing 1-4 heteroatoms selected from N, O and S as ring members; R 6 Independently selected from H, -CN, -OH, C1-C4 alkyl and C1-C4 alkoxy; R 7 independently selected from C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 haloalkyl, saturated and unsaturated 4-7 membered heterocyclyl containing 1-2 heteroatoms selected from N, O and S as ring members, aryl and heteroaryl containing 1-4 heteroatoms selected from N, O and S as ring members; X is selected from -OH, -NH2, -CN, -NH(CO)(C1-C4 alkyl), C1-C4 alkyl, C1-C4 haloalkyl and C1-C4 alkoxy; Y 1 , Y 2 , Y 3 , Y 4 , Y 5 and Y 6 Independently selected from N and -CR 8 , where R 8 is selected from the group consisting of H, F, Cl, CN, CH3 and CF3; and n is an integer selected from 1-3.

2. The compound according to claim 1, and / or a stereoisomer, a stable isotope or a pharmaceutically acceptable salt or solvate of said compound, wherein A 1 is a cyclic group selected from phenyl, pyridine, pyrimidine, pyrazine, pyridazine, pyrazole, thiophene, thiazole and oxazole, and wherein the cyclic group is optionally substituted by 1-3 groups independently selected from halogen elements, CN, C1-C4 alkyl and C1-C4 haloalkyl.

3. The compound according to claim 1 or 2, and / or a stereoisomer, a stable isotope or a pharmaceutically acceptable salt or solvate of said compound, wherein A 1 is a cyclic group selected from the following: The bond marked with an asterisk * represents the L of the connecting formula I 1 key.

4. The compound of claim 1, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of said compound, wherein A 1 is a cyclic group selected from 5- to 6-membered heteroaryl groups, wherein the 5- to 6-membered heteroaryl groups contain 1-2 heteroatoms independently selected from N, O and S as ring members, and wherein the cyclic group is optionally substituted by 1-3 groups independently selected from halogen elements, CN, C1-C4 alkyl and C1-C4 haloalkyl.

5. The compound according to claim 1 or 4, and / or a stereoisomer, a stable isotope or a pharmaceutically acceptable salt or solvate of said compound, wherein A 1 is a cyclic group selected from pyridine, pyrimidine, pyrazine, pyridazine, pyrazole, thiophene, thiazole and oxazole, and wherein the cyclic group is optionally substituted by 1-3 groups independently selected from halogen elements, CN, C1-C4 alkyl and C1-C4 haloalkyl.

6. The compound according to any one of claims 1 to 5, and / or a stereoisomer, a stable isotope or a pharmaceutically acceptable salt or solvate of said compound, wherein A 1 is a cyclic group selected from the following: The bond marked with an asterisk * represents the L of the connecting formula I 1 key.

7. The compound of claim 1, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of said compound, wherein A 1 It is a cyclic group selected from 6-membered heteroaryl, wherein the 6-membered heteroaryl contains 1-2 heteroatoms independently selected from N, O and S as ring members, and wherein the cyclic group is optionally substituted by 1-3 groups independently selected from halogen elements, CN, C1-C4 alkyl and C1-C4 haloalkyl.

8. The compound of claim 1 or 7, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of said compound, wherein A 1 is a cyclic group selected from pyridine, pyrimidine, pyrazine and pyridazine, and wherein the cyclic group is optionally substituted by 1-3 groups independently selected from halogen elements, CN, C1-C4 alkyl and C1-C4 haloalkyl.

9. The compound according to any one of claims 1 to 8, and / or a stereoisomer, a stable isotope or a pharmaceutically acceptable salt or solvate of said compound, wherein A 1 is a cyclic group selected from the following: The bond marked with an asterisk * represents the L of the connecting formula I 1 key.

10. The compound according to any one of claims 1 to 9, and / or a stereoisomer, a stable isotope or a pharmaceutically acceptable salt or solvate of said compound, wherein A 2 is a group selected from the following: The bond marked with an asterisk * represents the L of the connecting formula I 2 key.

11. The compound according to any one of claims 1 to 10, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of said compound, wherein A 2 yes The bond marked with an asterisk * represents the L of the connecting formula I 2 key.

12. The compound according to any one of claims 1 to 11, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of said compound, wherein L 1 is a group selected from the following: Where R 3 and R 4 are independently selected from H and CH3; or wherein R 3 and R 4 Together they form a group selected from a carbonyl group and a 3- to 4-membered cycloalkyl group.

13. The compound according to any one of claims 1 to 12, and / or a stereoisomer, a stable isotope or a pharmaceutically acceptable salt or solvate of said compound, wherein L 1 is a group selected from the following: The bond marked with an asterisk * represents the bond connecting X of formula I.

14. The compound according to any one of claims 1 to 13, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of said compound, wherein L 1 yes The bond marked with an asterisk * represents the bond connecting X of formula I.

15. The compound according to any one of claims 1 to 14, and / or a stereoisomer, a stable isotope or a pharmaceutically acceptable salt or solvate of said compound, wherein L 2 It is a group selected from CO and C1-C6 alkylene.

16. The compound according to any one of claims 1 to 15, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of said compound, wherein L 2 is a group selected from CO and -CH2-.

17. The compound according to any one of claims 1 to 16, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of said compound, wherein L 2 It is -CH2-.

18. The compound according to any one of claims 1 to 17, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of said compound, wherein R 1 Yes-CN.

19. The compound according to any one of claims 1 to 18, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of said compound, wherein each R 2 Independently selected from halogen elements, -OH, -CN, C1-C6 alkyl, C1-C6 haloalkyl and C1-C6 alkoxy.

20. The compound according to any one of claims 1 to 19, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of said compound, wherein each R 2 Independently selected from halogen elements and C1-C6 alkoxy groups.

21. The compound according to any one of claims 1 to 20, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of said compound, wherein each R 2 It is -OCH3.

22. The compound of any one of claims 1 to 21, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of said compound, wherein X is selected from -OH, -NH2, -NH(CO)CH3, and -CH2CH3.

23. The compound of any one of claims 1 to 22, and / or a stereoisomer, a stable isotope or a pharmaceutically acceptable salt or solvate of said compound, wherein X is selected from -OH and -NH2.

24. The compound of any one of claims 1 to 23, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of said compound, wherein X is -OH.

25. The compound of any one of claims 1 to 24, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of said compound, wherein Y 2 is N, and Y 1 , Y 3 and Y 4 Independently selected from -CR 8 , where R 8 Selected from H, F, Cl, CN, CH3 and CF3.

26. The compound of any one of claims 1 to 24, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of said compound, wherein Y 2 and Y 4 is N, and Y 1 and Y 3 Independently selected from -CR 8 , where R 8 Selected from H, F, Cl, CN, CH3 and CF3.

27. A compound as described in any one of claims 1 to 24, and / or a stereoisomer, a stable isotope or a pharmaceutically acceptable salt or solvate of said compound, wherein Y 1 and Y 3 is N, and Y 2 and Y 4 Independently selected from -CR 8 , where R 8 Selected from H, F, Cl, CN, CH3 and CF3.

28. A compound as described in any one of claims 1 to 27, and / or a stereoisomer, a stable isotope or a pharmaceutically acceptable salt or solvate of said compound, wherein Y 5 is N and Y 6 Selected from -CR 8 , where R 8 Selected from H, F, Cl, CN, CH3 and CF3.

29. The compound of any one of claims 1 to 27, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of said compound, wherein Y 6 is N and Y 5 Selected from -CR 8 , where R 8 Selected from H, F, Cl, CN, CH3 and CF3.

30. The compound of any one of claims 1 to 29, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate thereof, wherein R 8 It's H.

31. The compound of any one of claims 1-30, and / or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate of said compound, wherein n is 1.

32. The compound of claim 1, wherein the compound is selected from the group consisting of compounds of Formula IA: and / or a stereoisomer, a stable isotope or a pharmaceutically acceptable salt or solvate of the compound, wherein A 1 , A 2 , L 1 , L 2 , R 1 , R 2 , X, Y 5 , Y 6 and n are the same as defined in claim 1.

33. The compound of claim 1, wherein the compound is selected from the group consisting of compounds of Formula IB: and / or a stereoisomer, a stable isotope or a pharmaceutically acceptable salt or solvate of the compound, wherein A 1 , A 2 , L 1 , L 2 , R 1 , R 2 , X, Y 5 , Y 6 and n are the same as defined in claim 1.

34. The compound of claim 1, wherein the compound is selected from the group consisting of compounds of Formula IC: and / or a stereoisomer, a stable isotope or a pharmaceutically acceptable salt or solvate of the compound, wherein A 1 , A 2 , L 1 , L 2 , R 1 , R 2 , X, Y 5 , Y 6 and n are the same as defined in claim 1.

35. The compound of claim 1, wherein the compound is selected from the group consisting of compounds of Formula ID: and / or a stereoisomer, a stable isotope or a pharmaceutically acceptable salt or solvate of the compound, wherein A 1 , A 2 , L 1 , L 2 , R 1 , R 2 , X, Y 1 , Y 2 , Y 3 , Y 4 and n are the same as defined in claim 1.

36. The compound of claim 1, wherein the compound is selected from the group consisting of compounds of Formula IE: and / or a stereoisomer, a stable isotope or a pharmaceutically acceptable salt or solvate of the compound, wherein A 1 , A 2 , L 1 , L 2 , R 1 , R 2 , X, Y 1 , Y 2 , Y 3 , Y 4 and n are the same as defined in claim 1.

37. The compound of claim 1, wherein the compound is selected from the group consisting of compounds of Formula IIA: and / or a stereoisomer, a stable isotope or a pharmaceutically acceptable salt or solvate of the compound, wherein A 1 , L 1 , L 2 , R 1 , R 2 , X, Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , Y 6 and n are the same as defined in claim 1.

38. The compound of claim 1, wherein the compound is selected from the group consisting of compounds of Formula IIB: and / or a stereoisomer, a stable isotope or a pharmaceutically acceptable salt or solvate of the compound, wherein A 1 , L 1 , L 2 , R 1 , R 2 , X, Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , Y 6 and n are the same as defined in claim 1.

39. The compound of claim 1, wherein the compound is selected from the group consisting of compounds of Formula IIC: and / or a stereoisomer, a stable isotope or a pharmaceutically acceptable salt or solvate of the compound, wherein A 1 , L 1 , L 2 , R 1 , R 2 , X, Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , Y 6 and n are the same as defined in claim 1.

40. The compound of claim 1, wherein the compound is selected from the group consisting of compounds of Formula IID: and / or a stereoisomer, a stable isotope or a pharmaceutically acceptable salt or solvate of the compound, wherein A 1 , L 1 , L 2 , R 1 , R 2 , X, Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , Y 6 and n are the same as defined in claim 1.

41. The compound of claim 1, wherein the compound is selected from the group consisting of compounds of Formula IIE: and / or a stereoisomer, a stable isotope or a pharmaceutically acceptable salt or solvate of the compound, wherein A 1 , L 1 , L 2 , R 1 , R 2 , X, Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , Y 6 and n are the same as defined in claim 1.

42. A compound selected from the group consisting of the following compounds, and / or stereoisomers, stable isotopes or pharmaceutically acceptable salts or solvates of said compounds:

43. A pharmaceutical composition comprising a compound according to any one of claims 1 to 42, and / or a stereoisomer, stable isotope or pharmaceutically acceptable salt or solvate of said compound, in admixture with at least one pharmaceutically acceptable carrier.

44. pharmaceutical composition as claimed in claim 43, described pharmaceutical composition also comprises at least one therapeutic adjuvant or therapeutic combination, described at least one therapeutic adjuvant or therapeutic combination is selected from chemotherapeutic agent and other anticancer agent, apoptosis regulator, immunopotentiator, the medicament for immunotherapy, immune checkpoint inhibitor, radiation, antitumor vaccine, the medicament for cytokine therapy, signal transduction inhibitor, other RET kinase inhibitor and kinase inhibitor.

45. The pharmaceutical composition of claim 44, wherein the at least one therapeutic adjunct or co-therapy is combined with the compound in a single dosage form, or the at least one therapeutic adjunct is administered simultaneously or sequentially as a separate dosage form.

46. ​​A method for treating a RET-related disease in a patient in need thereof, the method comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound according to any one of claims 1-42, and / or a stereoisomer, stable isotope or pharmaceutically acceptable salt or solvate of the compound, or a pharmaceutical composition according to any one of claims 43-45.

47. The method of claim 46, wherein the method comprises determining whether the disease in the patient is a RET-related disease, and administering to a patient in need of such treatment a therapeutically effective amount of a compound as described in any one of claims 1-42, and / or a stereoisomer, stable isotope or pharmaceutically acceptable salt or solvate of the compound, or a pharmaceutical composition as described in any one of claims 43-45.

48. The method of claim 46 or claim 47, wherein the RET-related disease is a RET-related cancer having a RET gene fusion, one or more point mutations in the RET gene, or a RET gene amplification, wherein the RET gene amplification causes overexpression of the RET gene, thereby resulting in a pathogenic increase in the activity of the kinase domain of the RET protein or the constitutively active kinase domain of the RET protein.

49. The method of claim 46 or claim 47, wherein the RET-related disease is irritable bowel syndrome or other gastrointestinal disorders having a RET gene fusion, one or more point mutations in the RET gene, or a RET gene amplification that causes overexpression of the RET gene, thereby resulting in a pathogenic increase in the activity of the kinase domain of the RET protein or the constitutively active kinase domain of the RET protein.

50. The method of claim 48, wherein the treatment comprises administering at least one therapeutic adjuvant or combination therapy selected from chemotherapeutic agents and other anticancer agents, apoptosis modulators, immunopotentiators, agents used in immunotherapy, immune checkpoint inhibitors, radiation, anti-tumor vaccines, agents used in cytokine therapy, signal transduction inhibitors, and kinase inhibitors.

51. The method of claim 50, wherein administering the compound is performed simultaneously or sequentially with administering the at least one therapeutic adjuvant.

52. The method of claim 51, wherein administering the at least one therapeutic adjunct comprises administration of an additional RET inhibitor, immunotherapy, or a combination thereof.

53. The method of claim 48, wherein the RET-associated cancer is selected from lung cancer, papillary thyroid cancer, medullary thyroid cancer, differentiated thyroid cancer, recurrent thyroid cancer, refractory differentiated thyroid cancer, multiple endocrine neoplasia type 2A or 2B (MEN2A or MEN2B, respectively), pheochromocytoma, parathyroid hyperplasia, breast cancer, pancreatic cancer, salivary gland cancer, Spitz tumor, colorectal cancer, papillary renal cell carcinoma, gastrointestinal mucosal ganglioneuroma, cervical cancer, ovarian cancer, and myeloproliferative carcinoma.

54. The method of any one of claims 46-53, wherein the compound of any one of claims 1-42, and / or a stereoisomer, stable isotope or pharmaceutically acceptable salt or solvate of said compound, or the pharmaceutical composition of any one of claims 43-45 is administered orally.

55. Use of the compound of any one of claims 1-42, and / or the stereoisomer, stable isotope or pharmaceutically acceptable salt or solvate of the compound, or the pharmaceutical composition of any one of claims 42-45 as a drug in the manufacture of a drug for treating RET-related diseases or in a medicine for treating RET-related diseases.

56. The use as claimed in claim 55, wherein the RET-related disease is a RET-related cancer, wherein the RET-related cancer has RET gene fusion, one or more point mutations in the RET gene, or RET gene amplification, wherein the RET gene amplification causes overexpression of the RET gene, thereby leading to a pathogenic increase in the activity of the kinase domain of the RET protein or the constitutively active kinase domain of the RET protein.

57. The use as claimed in claim 56, wherein the RET-related disease is irritable bowel syndrome or other gastrointestinal disorders, and the irritable bowel syndrome or other gastrointestinal disorders have RET gene fusion, one or more point mutations in the RET gene, or RET gene amplification, and the RET gene amplification causes overexpression of the RET gene, thereby leading to a pathogenic increase in the activity of the kinase domain of the RET protein or the constitutively active kinase domain of the RET protein.

58. The use of claim 56 or claim 57, wherein the RET-related cancer is selected from lung cancer, papillary thyroid cancer, medullary thyroid cancer, differentiated thyroid cancer, recurrent thyroid cancer, refractory differentiated thyroid cancer, multiple endocrine neoplasia type 2A or 2B (MEN2A or MEN2B, respectively), pheochromocytoma, parathyroid hyperplasia, breast cancer, pancreatic cancer, salivary gland cancer, Spitz tumor, colorectal cancer, papillary renal cell carcinoma, gastrointestinal mucosal ganglioneuroma, cervical cancer, ovarian cancer and myeloproliferative cancer.

59. The use according to any one of claims 55 to 58, wherein the medicament is formulated for oral administration.

60. The compound according to any one of claims 1 to 42, and / or the stereoisomer, stable isotope or pharmaceutically acceptable salt or solvate of the compound, or the pharmaceutical composition according to claims 43 to 45 for use in the treatment of a RET-related disease.

61. The compound or pharmaceutical composition for use of claim 60, wherein the RET-related disease is a RET-related cancer having a RET gene fusion, one or more point mutations in the RET gene, or a RET gene amplification, which results in overexpression of the RET gene, thereby leading to a pathogenic increase in the activity of the kinase domain of the RET protein or the constitutively active kinase domain of the RET protein.

62. A compound or pharmaceutical composition for use as described in claim 60, wherein the RET-related disease is irritable bowel syndrome or other gastrointestinal disorders, and the irritable bowel syndrome or other gastrointestinal disorders have RET gene fusion, one or more point mutations in the RET gene, or RET gene amplification, which causes overexpression of the RET gene, thereby resulting in a pathogenic increase in the activity of the kinase domain of the RET protein or the constitutively active kinase domain of the RET protein.

63. A compound or pharmaceutical composition for use as described in claim 60 or claim 61, wherein the RET-related disease is a RET-related cancer, and the use comprises determining whether the cancer in a patient is a RET-related cancer, and administering a therapeutically effective amount of the compound or pharmaceutical composition to a patient in need of such treatment.

64. A compound for use or pharmaceutical composition as described in claim 61 or claim 63, wherein the RET-related cancer is selected from lung cancer, papillary thyroid cancer, medullary thyroid cancer, differentiated thyroid cancer, recurrent thyroid cancer, refractory differentiated thyroid cancer, multiple endocrine neoplasia type 2A or 2B (MEN2A or MEN2B, respectively), pheochromocytoma, parathyroid hyperplasia, breast cancer, pancreatic cancer, salivary gland cancer, Spitz tumor, colorectal cancer, papillary renal cell carcinoma, gastrointestinal mucosal ganglioneuroma, cervical cancer, ovarian cancer and myeloproliferative carcinoma.

65. A method for inhibiting the in vitro or in vivo RET kinase activity of RET-related cancer cells using a compound described in any one of claims 1-42, and / or a stereoisomer, stable isotope or pharmaceutically acceptable salt or solvate of the compound, wherein the RET-related cancer cells have a RET gene fusion, one or more point mutations in the RET gene, or a RET gene amplification, wherein the RET gene amplification causes overexpression of the RET gene, thereby resulting in a pathogenic increase in the activity of the kinase domain of the RET protein or the constitutively active kinase domain of the RET protein.

66. A method for treating RET-related cancer in a patient who has developed resistance to a RET inhibitor, the method comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of any one of claims 1-42, and / or a stereoisomer, stable isotope or pharmaceutically acceptable salt or solvate of the compound, or a pharmaceutical composition of any one of claims 43-45.

67. The method of claim 66, wherein the method comprises: (a) determining RET mutations in cancer cells in samples from patients who have developed resistance to previous treatment with a RET inhibitor; and (b) administering the compound of any one of claims 1 to 42, and / or a stereoisomer, a stable isotope or a pharmaceutically acceptable salt or solvate of the compound, or the pharmaceutical composition of any one of claims 43 to 45.

68. The method of claim 66 or claim 67, wherein the prior treatment comprises administration of at least one therapeutic adjuvant or combination therapy selected from chemotherapeutic agents or other anticancer agents, apoptosis regulators, immunopotentiators, agents for immunotherapy, immune checkpoint inhibitors, radiation, anti-tumor vaccines, agents for cytokine therapy, signal transduction inhibitors, and kinase inhibitors.

69. The method of claim 68, wherein administering the therapeutic adjunct comprises administration of an additional RET inhibitor, immunotherapy, or a combination thereof.

70. A kit comprising a compound according to any one of claims 1-42 or a pharmaceutically acceptable salt of the compound, or a pharmaceutical composition according to any one of claims 43-45 and a therapeutic aid.